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RIASSUNTO 
La tesi è basata sull’analisi dei meccanismi responsabili della patogenesi e resistenza al 
trattamento con inibitori tirosino-chinasici (TKI) nei pazienti con leucemia acuta linfoblastica 
(LAL) Philadelfia positiva (Ph+). Tale forma di leucemia rappresenta il più frequente e 
prognosticamente sfavorevole sottotipo di LAL dell’adulto. In particolare i suoi obbiettivi sono 
stati quelli di analizzare, con una metodica ad alta risoluzione (SNP array), la frequenza e 
l’estensione delle delezioni nel locus 9p21 in 112 pazienti adulti con LAL Ph+ e di determinare i 
principali meccanismi di inattivazione, al fine di definire nuovi marcatori diagnostici e 
prognostici ed identificare nuovi meccanismi coinvolti nella progressione leucemica. La regione 
cromosomica 9p21 è un sito frequentemente alterato in differenti tumori umani, sia solidi che 
ematologici. Questo locus codifica per importanti proteine coinvolte nella regolazione del ciclo 
cellulare e nell’apoptosi (ARF, CDKN2A e di CDKN2B), inoltre viene trascritto un RNA non 
codificante, ANRIL. L’analisi dei dati di SNP ha dimostrato alterazioni genomiche alla diagnosi 
in CDKN2A/ARF e in CDKN2B rispettivamente nel 29 e nel 25% dei pazienti alla diagnosi . 
Mentre ANRIL era deleto nel 29% dei casi. Nel 72% dei casi le delezioni erano monoalleliche. In 
particolare, nel 43% dei casi la delezione era limitata ai geni CDKN2A e CDKN2B, mentre nel 
57% si estendeva anche ai geni vicini o all’intero cromosoma 9. Nel 28%, invece, la delezione 
era biallelica e nella maggior parte di questi casi era limitata ai soli geni CDKN2A e CDKN2B. 
Al fine di valutare se le delezioni di CDKN2A/B potessero essere coinvolte nella progressione 
leucemica, abbiamo analizzato le alterazioni genetiche nel locus 9p21 (30 pazienti) al momento 
della ricaduta. Solo in CDKN2A/ARF abbiamo riscontrato un incremento quasi significativo (p = 
0.06) nella percentuale di delezione (47%) rispetto a quella della diagnosi. Sia alla diagnosi che 
al relapse le delezioni erano in eterozigosi nella maggior parte dei casi. Per verificare se nella 
nostra casistica anche le mutazioni puntiformi potessero inattivare il locus 9p21 abbiamo 
analizzato la sequenza di tutti gli esoni di ARF, CDKN2A e di CDKN2B. Mutazioni sono state 
raramente riscontrate, e solo una, ha comportato una sostituzione amminoacidica. In conclusione 
si può affermare che l’inattivazione degli oncosoppressori CDKN2A e ARF è un evento frequente 
nelle LAL Ph+, che il principale meccanismo di inattivazione è dato dalle delezioni genomiche, 
mentre le mutazioni che comportano la sostituzione amminoacidica sono rare, e che le delezioni 
sono frequentemente acquisite al momento della progressione leucemica e risultano essere un 
sfavorevole marcatore prognostico. 
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ABSTRACT 
This 9p21 locus, encode for important proteins involved in cell cycle regulation and apoptosis 
containing the p16/CDKN2A (cyclin-dependent kinase inhibitor 2a) tumor suppressor gene and 
two other related genes, p14/ARF and p15/CDKN2B. This locus, is a major target of inactivation 
in the pathogenesis of a number of human tumors, both solid and haematologic, and is a frequent 
site of loss or deletion also in acute lymphoblastic leukemia (ALL) ranging from 18% to 45% 1. 
In order to explore, at high resolution, the frequency and size of alterations affecting this locus in 
adult BCR-ABL1-positive ALL and to investigate their prognostic value, 112 patients (101 de 
novo and 11 relapse cases) were analyzed by genome-wide single nucleotide polymorphisms 
arrays and gene candidate deep exon sequencing. Paired diagnosis-relapse samples were further 
available and analyzed for 19 (19%) cases.  
CDKN2A/ARF and CDKN2B genomic alterations were identified in 29% and 25% of newly 
diagnosed patients, respectively. Deletions were monoallelic in 72% of cases and in 43% the 
minimal overlapping region of the lost area spanned only the CDKN2A/2B gene locus. The 
analysis at the time of relapse showed an almost significant increase in the detection rate of 
CDKN2A/ARF loss (47%) compared to diagnosis (p = 0.06). Point mutations within the 9p21 
locus were found at very low level with only a non-synonymous substition in the exon 2 of 
CDKN2A. Finally, correlation with clinical outcome showed that deletions of CDKN2A/B are 
significantly associated with poor outcome in terms of overall survival (p = 0.0206), disease 
free-survival (p = 0.0010) and cumulative incidence of relapse (p = 0.0014).  
The inactivation of 9p21 locus by genomic deletions is a frequent event in BCR-ABL1-positive 
ALL. Deletions are frequently acquired at the leukemia progression and work as a poor 
prognostic marker.  
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1.1 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PHILADELPHIA 
CHROMOSOME POSITIVE (Ph+) 
The Philadelphia chromosome (Ph) is the most common cytogenetic abnormality associated with 
adult acute lymphoblastic leukemia (ALL). Age is an important determinant of prognosis and 
outcome for patients with acute lymphoblastic leukemia. Long-term survival rates approach 80% 
in children aged <5 years but decrease to approximately 50% to 60% in adolescents and young 
adults, to approximately 30% in adults ages 45 to 54 years, and rarely exceed 15% in older 
adults. Prognostic changes that occur with increasing age may be attributable in part to age-
dependent increases in unfavorable cytogenetic abnormalities. Although Ph+ ALL occurs in only 
approximately 5% of patients with ALL aged <20 years, the incidence escalates to 33% in 
patients aged 40 years and is 49% in patients aged >40 years; the incidence decreases to 35% in 
patients aged >60 years 2. 
1.2 MOLECULAR BASIS OF THE PHILADELPHIA CHROMOSOME 
TRANSLOCATION 
The Philadelphia chromosome is observed in 95% of adult chronic myeloid leukaemia (CML), 
15–20% of adult ALL, 3–5% of childhood ALL and very rarely in acute myeloid leukaemia 
(AML)3,4. It was the first specific genetic lesion identified in a human cancer and it results from 
a reciprocal translocation (t) between chromosomes 9 and 22 [t(9;22)]. This translocation creates 
a fusion of human homologue of the Abelson Murine Leukaemia virus ABL on 9q34 with 
breakpoint cluster region BCR on 22q11. Bcr-Abl fusion proteins are constitutively active 
tyrosine kinases that can alter multiple signaling pathways, contributing to tumor growth and 
proliferation. The breakpoint may occur within 1 of 4 sites on the BCR gene to produce 3 
proteins of different sizes: p190, p210, and p230 2. Immunophenotyping is pre-B (CD19+, 
CD10+), often associated to the expression of myeloid markers (CD13+, CD33+).  
1.2.1 Structure and functions of the Bcr and Abl proteins 
The BCR and ABL genes are expressed ubiquitously.  
Bcr is a 160-kd cytoplasmic protein with several functional domains. The N-terminal 426 amino 
acids of Bcr, encoded by the first exon, are retained in all Bcr-Abl fusion protein isoforms. This 
region contains a serine-threonine kinase domain, whose only known substrates are Bcr and Bap-
1 (a member of the 14-3-3 family of proteins), and two serine/threonine–rich regions that bind 
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Src homology (SH)2 domains. The proximal SH2-binding domain is essential for transformation 
of rat fibroblasts by Bcr-Abl 5. The two key motifs of the first BCR exon are tyrosine 177 and the 
coiled-coil domain contained in amino acids 1 to 63. Phosphorylated tyrosine 177 forms a 
binding site for Grb-2 (an adapter molecule that links BCR to the Ras pathway) and is required 
for the induction of myeloid leukemia 6. The coiled-coil is crucial for dimerization of Bcr-Abl 7, 
which in turn is required for activation of Abl kinase activity and oncogenicity of Bcr-Abl. BCR 
regions of exon 1 are not essential to oncogenicity but influence the specific phenotype of the 
leukaemia (Fig. 1.1).  
The ABL gene, the human homolog of v-abl (the oncogene of the Abelson murine leukemia 
virus), codes for a 145-kd nonreceptor tyrosine kinase. Two isoforms exist that differ in the first 
exon (1a and 1b). Only Abl type 1b protein contains a myristoylation site and, therefore, can be 
anchored to the plasma membrane. Three domains located toward the N-terminus of Abl are 
named after their homology to the respective domains in Src, the prototype non-receptor tyrosine 
kinase. The SH1 domain carries the tyrosine kinase function, the SH2 domain binds 
phosphotyrosine-containing consensus sites, and the SH3 domain binds to proline-rich consensus 
sequences in proteins like Crk 8 and Crkl 9. Abl differs from Src in having a long (~90-kd) C-
terminal region that contains actin-and DNA-binding domains 7, three nuclear localization 
signals, and one nuclear export signal. Another unique feature of Abl is the N-terminal ‘‘Cap’’ 
region that is critical to the regulation of kinase activity. Abl is expressed predominantly in the 
nucleus10 but shuttles between nucleus and cytoplasm. The functions of the Abl protein are 
complex and include cell cycle inhibition, cellular responses to genotoxic stress 11, and signal 
transduction from growth factor receptors and from integrins 12 (Fig. 1.1). 
 
Fig. 1.1 Schematic representation of the Abl (a) and Bcr (b) proteins. There are several important domains that 
make up ABL and BCR proteins 13.  
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1.2.2 BCR-ABL fusion gene 
1.2.2.1 Breakpoints in ABL 
Breakpoints within the ABL gene can occur anywhere within a 50 segment that extends for over 
300 kilobases (kb) 14. Typically, breakpoints are within intronic sequences, most frequently 
between the two alternative first exons of ABL. Thus, BCR-ABL fusion genes may contain both 
exons 1b and 1a, exon 1a alone, or neither of the alternative first exons. BCR-ABL mRNA lacks 
exon 1, regardless of the structure of the fusion gene, with the transcript consisting of BCR exons 
fused directly to ABL exon a2. 
1.2.2.2 Breakpoints in BCR 
The breakpoints within the BCR gene on chromosome 22 are found within three defined regions. 
In 95% of patients with CML and approximately one third of patients with ALL, the BCR gene is 
truncated within a 5.8-kb region known as the major breakpoint cluster region. This region 
contains five exons, originally named b1 to b5, but now referred to as e12 to e16, according to 
their true positions in the gene. Most breakpoints are within introns immediately downstream of 
exon 13 (b2) or exon 14 (b3). Because processing of BCR-ABL mRNA results in the joining of 
BCR exons to ABL exon a2, hybrid transcripts are produced that have an e13a2 (b2a2) or an 
e14a2 (b3a2) junction. In both cases, the mRNA consists of an 8.5-kb sequence that encodes a 
210-kd fusion protein, p210 Bcr-Abl (Fig. 2). In two-thirds of patients with Ph+ ALL and in rare 
cases of CML and AML, the breakpoint in BCR occurs in a region upstream of the major 
breakpoint cluster region known as the minor breakpoint cluster region. This region consists of 
the 54.4-kb intron between the two alternative second exons of the BCR gene, e20 and e2. BCR-
ABL fusion genes that have breakpoints within the minor breakpoint cluster region contain both 
BCR alternative first exons (e1 and e10) together with the alternative second exon (e20). The 
hybrid mRNA consists of sequences that are approximately 7 kb in length in which exon e1 from 
BCR is joined to exon a2 of ABL. The translated product is a 190-kd fusion protein, p190 Bcr-
Abl (also referred to as p185 Bcr-Abl). Interestingly, transcripts with an e1a2 junction are 
detectable at very low levels in patients with a major breakpoint cluster region rearrangement. 
The third defined breakpoint cluster region within the BCR gene was named ‘‘micro’’ breakpoint 
cluster region 15. In this case, the breaks occur within a 30 segment of the BCR gene between 
exons e19 and e20 (known as c3 and c4 in the original nomenclature) (Fig. 1.2). Transcription of 
the hybrid gene yields an e19a2 BCR-ABL fusion transcript that encodes a 230-k protein, p230 
BCR-ABL. 
11 
 
 
 
 
 
 
The p190 BCR-ABL fusion gene occurs in about 90% of children with Ph+ ALL and between 
50% and 80% of adults with Ph+ ALL. The p210 BCR-ABL gene constitutes the rest of the Ph+ 
ALL population. The p230 BCR-ABL mutation is associated with Ph+ chronic neutrophilic 
leukemia 2. 
Fig. 1.2 Three BCR-ABL variants and association of leukemia types. (A) Locations of the breakpoints in the 
ABL and BCR genes and (B) structure of the chimeric BCR-ABL mRNA transcripts derived from the various 
breaks. (C) Functional domains of p210 BCR-ABL. 
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1.2.3 Mechanisms of BCR-ABL-mediated leukaemogenesis  
Tyrosine kinase enzymatic activity is central to cellular signaling and growth, and constitutively 
elevated kinase activity has been associated with transformation in several systems. The Abl 
protein is a non-receptor tyrosine kinase whose enzymatic activity is under close physiologic 
control 16 . In contrast, Bcr-Abl proteins are constitutively active tyrosine kinases. The degree of 
transforming activity of Bcr-Abl correlates with the degree of tyrosine kinase activity. p190 Bcr-
Abl, which has higher tyrosine kinase activity, is therefore associated with the development of 
the more aggressive acute leukemia phenotype, while p210 Bcr-Abl plays a role in the more 
indolent chronic leukemia phenotype. 
1.2.3.1 Altered cellular adhesion 
In normal hematopoiesis, progenitor cells adhere to the stromal cells of the bone marrow and 
their associated extracellular matrix. The latter contains proteins such as fibronectin that function 
as adhesive ligands for receptors expressed on the surface of hematopoietic progenitor cells. 
Current thinking holds that the process of adhesion is essential for the regulation of 
hematopoiesis, providing a means of anchoring progenitors within the vicinity of cytokine-
secreting cells 17, exposing them to specific signals that determine their fate. Ph+ progenitors 
exhibit reduced adhesion to stromal cells and the extracellular matrix 18, which ‘‘liberates’’ them 
from the regulatory signals that are supplied to normal, adherent hematopoietic progenitors. It 
also may explain why their homing to the bone marrow is disturbed, leading to the appearance of 
immature cells in the peripheral blood. There is evidence that the function of β integrins on the 
surface of CML progenitor cells is perturbed, the net effect being reduced adhesion and 
increased proliferation 17. In addition, migration, in response to certain chemokines such as MIP-
1a, is abnormally high 19. 
1.2.3.2 Activation of mitogenic signaling pathways  
Bcr-Abl is known to activate several signaling pathways with mitogenic potential 20. It is 
important to remember that in many cases, the available data comes from experiments in Bcr-
Abl–positive cell lines, and activation of some of these pathways in primary CML cells has yet 
to be verified. 
Ras and the mitogen-activated protein kinase pathways 
Bcr-Abl binds directly to proteins that activate Ras 21. Autophosphorylation of tyrosine 177 
generates a binding site for the adapter molecule Grb-2 5. Grb- 2 associates with the Sos protein, 
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which stimulates the conversion of the inactive GDP-bound form of Ras to the active GTP-
bound state 21. Ras also may be activated by two other adapter molecules, Shc and CrkL, which 
are substrates of Bcr-Abl 22. Although CrkL appears to be necessary for the transformation of 
fibroblasts by Bcr-Abl, direct binding of Crkl to Bcr-Ablis not required for the transformation of 
myeloid cells. Activated Ras binds to the serinethreonine kinase Raf-1, recruiting it to the plasma 
membrane where it is activated by tyrosine phosphorylation and initiates a signaling cascade by 
way of the mitogen-activated protein kinase (MAPK) pathway. Grb-2 also recruits the 
scaffolding adapter Gab2, which then is phosphorylated by Bcr-Abl, resulting in activation of 
phosphatidylinositol 3 (PI-3) kinase/Akt and Ras/Erk 23. Bcr-Abl activates different types of 
mitogen-activated protein kinases, including extracellular signal–related kinases (ERK)-1/2 and 
JNK or stress-activated protein kinase. Ultimately, these pathways regulate gene transcription. 
Janus kinase–signal transducer and activator of transcription pathway.  
Phosphorylation of members of the signal transducer and activator of transcription (STAT) 
family of transcription factors has been reported in Bcr-Abl–positive cell lines24 and in primary 
CML cells. Physiologically, STATs are phosphorylated by Janus kinases (Jak) that are 
downstream of growth factor receptors. In contrast, phosphorylation of STAT5 in Bcr-Abl–
expressing myeloid cells appears to be mediated by the Src family kinase, Hck, which binds the 
SH2 and SH3 domains of Bcr-Abl25. There is evidence that activation of STAT5 by p210 Bcr-
Abl contributes to malignant transformation of K562 cells26 and inhibits apoptosis by up-
regulating the transcription of Bcl-xL27. STAT5, however, is not required for leukemia induction 
by Bcr-Abl in mice, casting doubt on its relevance in a more physiologic context. Interestingly, 
p190 Bcr-Abl differs from p210 Bcr-Abl in that it also is able to activate STAT6. It remains to 
be seen whether the predominantly lymphoblastic phenotype associated with p190 Bcr-Abl is 
related to this property of the shorter form of the oncoprotein. 
Phosphatidylinositol 3 kinase pathway.  
Proliferation of BCR-ABL–positive cell lines and primary cells is dependent on PI-3 kinase. Bcr-
Abl apparently activates this pathway by forming a multimeric complex with PI-3 kinase, 
p120Cbl, and the adaptor molecules Crk and CrkL. In BCR-ABL–expressing cells, activated PI-3 
kinase stimulates the serine-threonine kinase Akt 28, which in turn phosphorylates the forkhead 
transcription factor, FKHRL1. The net result of activating this pathway appears to be the 
proteasome-mediated degradation of the key cell cycle inhibitor p27Kip1, although the precise 
intermediates are unknown. Activated Akt may function in an antiapoptotic capacity. A key 
substrate of Akt is the proapoptotic protein or ‘‘death agonist’’ Bad. Bad promotes cell death by 
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binding to and thereby inactivating the antiapoptotic Bcl-2 and Bcl-xL. Thus, phosphorylation of 
Bad by Akt may prevent it from binding to these proteins, resulting in reduced apoptosis. Indeed, 
increased Bad phosphorylation was seen in BCR-ABL–positive cells; however, even with Bad 
completely dephosphorylated, a fraction of cells survived, indicating the existence of Bad-
independent survival pathways. 
Myc pathway.  
Myc is classed as a proto-oncogene because it is overexpressed in many human malignancies. As 
a transcription factor and immediate early response gene, Myc converts mitogenic signals to 
alterations of gene expression. Not surprisingly, Myc targets include genes related to cell cycle 
and apoptosis. Within Bcr-Abl, the SH2 domain 29 and the C-terminus are required for full 
activation of Myc. It recently has been shown that Jak2 is involved in Myc induction by Bcr-Abl, 
apparently by way of induction of Myc mRNA and by stabilization of the protein.  
1.2.3.3 Inhibition of apoptosis 
Apoptosis caused by growth factor withdrawal is eliminated when factor dependent cell lines are 
transfected with exogenous BCR-ABL. The mechanisms by which Bcr-Abl inhibits apoptosis in 
cell lines are not well understood. The release of cytochrome C from mitochondria, a 
prerequisite for caspase-3 activation, apparently is blocked in BCR-ABL–expressing cell lines. 
Members of the Bcl-2 family of proteins may be involved in mediating the antiapoptotic effect of 
Bcr-Abl. Up-regulation of Bcl-2 by Bcr-Abl has been demonstrated in two different cellular 
contexts: one dependent on the Ras pathway and the other on the PI-3 kinase pathway. Bcl-2 
targets Raf-1 to mitochondria where it inactivates the proapoptotic protein Bad by 
phosphorylating it on serine residues 30. Down-regulation of interferon consensus sequence 
binding protein (ICSBP) by Bcr-Abl also has been implicated as an important antiapoptotic 
event; conversely, ICSBP antagonizes Bcr-Abl by decreasing Bcl-2 expression. Another 
regulator of apoptosis targeted by Bcr-Abl is Bcl-xL, the expression of which is dependent of 
STAT5 activation. Surprisingly, a recent report has demonstrated that Bcr-Abl can actively 
induce apoptosis when trapped in the nucleus 31. Treatment of human and murine Bcr-Abl–
positive cell lines with imatinib stimulated entry of the oncoprotein into the nucleus.  
1.2.3.4 Proteasomal degradation 
It recently was reported that Bcr-Abl tyrosine kinase activity induced the proteasome-mediated 
degradation of the ABL-interactor proteins Abi-1 and Abi-2 30. Bcr-Abl was found to cause 
down-regulation of the DNA repair protein DNA-PKcs in cell lines. Loss of DNA-PKcs activity 
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was correlated with impaired DNA repair and may facilitate the acquisition of additional genetic 
lesions that lead to disease progression. Another important degradation target is the cell p27, a 
crucial inhibitor of progression from the G1 to the S phase of the cell cycle. Furthermore, Bcr-
Abl can stabilize the expression of Mdm2, a protein that targets the tumor suppressor p53 for 
ubiquitination, which also would promote genomic instability 32. 
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1.3 DISCOVERY OF NOVEL ALTERATIONS IN ALL PH+ 
The recent coming of new “genome-wide” techniques, like gene expression profiling (GEP) and 
analysis of single nucleotide polymorphism (SNP) arrays has enabled to identify multiple novel 
genetic alterations targeting key cellular pathways, including lymphoid differentiation, cell cycle, 
tumor suppression, apoptosis and drug responsiveness. By GEP analysis, several down/up-
expressed genes have been identified. By genome-wide SNP array analysis of leukaemia blast 
cells of paediatric and adult CML blastic phases and Ph+ ALL patients 33, the presence of three 
frequent genetic deletions affecting IKZF1 (IKAROS), PAX5 deletions (Fig. 1.3) and the 
CDKN2A/B locus was identified.  
 
 
 
 
 
Fig. 1.3 Schematic representation of PAX5 deletion in a patient with Ph+ ALL as detected by SNP array 
analysis. The interrupted blue line represents the diploid genome (2) in the region containing MELK, PAX5 and 
ZCCHC7 genes. Deletion is represented by a stretch of SNPs, below the level of the diploid line (1). Copy number 
variations (CNVs) are represented by grey boxes 34. 
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IKZF1 and PAX5 encode transcription factors required for normal lymphoid development. 
CDKN2A/B locus encodes three tumour suppressor genes that are widely inactivated in many 
human cancers. At diagnosis, 84% of patients had already sustained IKFZ1 deletions and more 
than 50% of patients exhibited PAX5 loss; mono- or biallelic losses, encompassing the entire 
CDKN2A (CDKN2A and ARF) and CDKN2B gene cluster were also recognized in half of the 
patients (Tab. 1.1). Several other recurring deletions were identified in BCR-ABL1 ALL, albeit at 
a lower frequency, including C20orf94, RB1, MEF2C and EBF1.  
 
Tab. 1.1 Frequency of deletions in Ph+ ALL (Modified from C. G. Mullighan, Gene and Development 2008) 35. 
 
 
a
 No significant differences in gene deletion frequencies were observed between 21 paediatric and 22 adult cases 
subjected to analysis. Study of the CDKN2A/B gene cluster in 41 of these cases by quantitative PCR using primers 
directed to each of the INK4A, ARF and INK4B exons indicated an overall deletion frequency of 64%. 
 
IKFZ1 deletions, limited to the gene in the majority of the cases, were mostly monoallelic and 
were responsible for the expression of a dominant-negative isoform 36. In T-cell ALL, the 
frequencies of IKFZ1 and PAX5 deletions were much lower (Tab. 1.1), consistent with findings 
that these two genes play key roles in regulating B-cell lineage commitment and differentiation 
37
. Although differentiation arrest is a distinctive feature of ALL, the manner by which IKFZ1 
and PAX5 inactivation collaborate with BCR-ABL to induce lymphoblastic leukemia is not yet 
understood. CDKN2A/B deletions occur in all lymphoid malignancies (Tab. 1.1), pointing to 
their general role in tumor suppression in both T- and B-cell ALL, as well as in many other 
tumor types. The fact that deletion of PAX5 and CDKN2A/B generally occurred together with 
IKFZ1 loss implies that disruption of each of these genes contributes independently to Ph+ B-
cell ALL 35. GEP is providing a new diagnostic marker and could identify some therapeutic 
targets, having a major impact on the way we diagnose and treat Ph+ leukaemia patients. 
Although considerable work remains to be done before these predictions are realized, our 
capacity to obtain these type of data continues to mature at a rapid speed. Thus, the fruits of GEP 
should soon help us to accurately identify specific leukaemia subtypes, abnormally expressed or 
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spliced genes and to select targeted therapies. For instance, recent GEP studies have identified a 
new ALL subtype with a gene-expression pattern resembling that of BCR-ABL1-positive ALL. 
This newly recognized group includes 15–20% of all precursor B-ALL cases and is associated 
with an unfavourable outcome. 
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1.4 9p21 LOCUS (INK4A/ ARF/ INK4B/ ANRIL) 
The chromosome 9p21 segment is a 40-kb region encoding two members of the INK4 family of 
Cyclin-Dependent Kinase inhibitors, CDKN2B (p15INK4B, ENSG00000147883) and CDKN2A 
(p16INK4A, ENSG00000147889), and one other related gene ARF (p14ARF), transcribed in an 
Alternative Reading Frame compared to CDKN2A; all of them encode critical factors for the 
regulation of cell cycle and for the influence on key physiological processes such as replicative 
senescence, apoptosis, and stem-cell self-renewal. 9p21 also contains a newly annotated non-
coding RNA, termed ANRIL (CDKN2BAS, ENSG00000240498), which spans 126.3 kb and 
overlaps at its 5’ end with CDKN2B, and it is transcribed from the opposite strand to CDKN2A/B 
(Fig. 1.4).  
 
 
 
Fig. 1.4 9p21 Locus NC_000009.11 Homo sapiens chromosome 9, GRCh37.p2 primary reference assembly 
MapViewer representation. Green bars show the length and the gene transcription verse. Blu bars show exons and 
red bars represent gene translation. Modified from NCBI MapViewer 
http://www.ncbi.nlm.nih.gov/nuccore/224589821 
 
CDKN2B and CDKN2A arose from a gene duplication event and are consequently very similar 
(77% amino acid sequence identity in humans). CDKN2A and ARF have different promoter and 
different first exons (1α and 1β, respectively) (Fig. 1.5), giving rise to products in alternate 
reading frames with no homology at the protein level and with distinct functions in the cells.  
  
Fig. 1.5 Organization of the CDKN2A
p14ARF are in black. The alternative first exons are transcribed from different promoters (arrows). *Denotes the 
p16INK4A and p14ARF termination codons. 
(p16) gene. Intronic sizes derived from http://snpper.chip.org are indicated.
Biochem Cell Biol, 2006 38. 
 
Exons 1α, 2, and 3 encode p16
Exons 1β, 2, and 3 encode p14
Therefore, the 9p21 locus has a un
frames (ORFs) that initiate in different first exons and continue in alternative reading frames in a 
common second exon. This unusual utilization of overlapping exonic sequences in mammalian 
cells enables a single gene to encode two completely unrelated protein products
the gene CDKN2A, in a more centromeric position, two exons encode for another tumor 
suppressor gene: CDKN2B (p15
Therefore on chromosome 9p21.3 there are
and ‘4’ (Appendix A), each conta
http://www.ncbi.nlm.nih.gov/nuccore/NM_000077.4
(http://www.ncbi.nlm.nih.gov/gene/1029
amino acids; isoform ‘1’ encodes p16
that is structurally unrelated to p16 but acts in cell cycle G1 control by stabilizing the tumor 
suppressor protein p53. 
The chromosome band 9p21 shows a 
where a multispecies sequence alignment shows 76% sequence identity and 94% sequence 
/ARF locus. The coding regions of p16INK4A are shown in 
Exon 1β of the p14ARF gene  is 19 kb upstream of exons 1
 Modified from Stuart J.Gallagher, 
INK4A
, which induces G1 cell cycle arrest via the Rb pathway. 
ARF
, which inhibits p53 degradation via binding to 
ique gene structure that generates two distinct open reading 
INK4B). 
 two main transcripts of CDKN2A
ins three exons and spans: 7,382 (according with NCBI, 
) and 26740 bp
), respectively. They encode proteins of 156 and 173 
 (INK4A), while isoform ‘4’ encodes p14
significant evolutionary conservation only in 
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gray, and those of 
α of the CDKN2A 
Int J 
Mdm2 39. 
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. Adjacent to 
 locus, isoforms ‘1’ 
 
 (ARF), a protein 
the exon 2, 
 similarity across six mammalian species
overlaps, the drop in conservation beyond the coding region of isoform 4 suggests that this 
isoform is more responsible for the observed conservation
The CDKN2A/ARF locus encodes proteins that
RB are at the heart of the two main tumour
to potentially oncogenic stimuli. Each pathway consists of several upstream regulators and 
downstream effectors. The pathways interact at several points, and 
(Fig. 1.6). p53 is a transcription factor that regulates apoptosis and cellular senescence by 
inducing the transcription of specific genes; the RB pathway directly regulates the cell cyc
hence cellular senescence, but is also important in apoptosis, probably by interacting with the 
p53 pathway. 
 
 
Fig. 1.6 The CDKN2A/ARF/CDKN2B
INK4 family of cyclin.dependent kina
p53 stabilization. Modified from Judith Campisi
  
. While exon 2 of both alternative reading frames 
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-suppressor pathways that control cellular responses 
cross
 
 locus and the p53 and RB tumour-suppressor pathways
se inhibitors bind to and inactivate CDK4/6. ARF inhibits MDM2, resulting in 
, Nature Reviews Cancer, 2003 42. 
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In the p53 pathway, signals such as DNA damage induce ARF. The tumor suppressor activity of 
ARF is largely ascribed to its ability to regulate p53 in response to aberrant growth or oncogenic 
stresses such as c-MYC activation. ARF increases p53 levels by sequestering Mdm2, which 
facilitates the degradation and inactivation of p53. One mechanism that has been proposed to 
explain how Mdm2 regulates p53 is that it acts as an E3 ubiquitin ligase to target p53 for 
proteasomal degradation. Although strong biochemical and genetic evidence link ARF and p53 
in tumor suppression, several p53-independent functions of ARF have also been reported. 
Moreover, ARF has been reported to interact with multiple proteins other than Mdm2, including 
E2F-1, MDMX, HIF-1α, topoisomerase I, MYC, and nucleophosmin (NPM). p53 has both 
transactivation and transrepression activity, and so controls the transcription of numerous genes. 
Among the p53 target genes are WAF1, an inhibitor of cyclin-dependent protein kinases (CDKs) 
that, among other activities, causes cell-cycle arrest, and BAX, which promotes apoptotic cell 
death. 
CDKN2A/B inhibit the complex between cyclin-dependent kinases 4/6 (CDK4/6) and cyclin D 
(the binding of the INK4 proteins INK4A/INK4B to CDK4/6 induces an allosteric change that 
abrogates the binding of these kinases to D-type cyclins) that phosphorylate, and therefore 
inactivate, RB during the mid-late G1 phase of the cell cycle (RB phosphorylation interrups its 
interactions with both histone deacetylase HDAC and E2F, enabling E2F to promote S phase 
entry). RB also controls the expression of numerous genes, although it does so primarily by 
recruiting transcription factors and chromatin remodelling proteins. One downstream 
consequence of RB activity is the inhibition of E2F activity, which is important for the 
transcription of several genes that are required for progression through the G1 and S phases of 
the cell cycle. RB also regulates p53 activity through a trimeric p53–Mdm2–RB complex 42,43. 
The ARF/CDKN2A/B proteins are established tumour suppressors altered in a range of human 
cancers including familial cutaneous malignant melanoma, glioma (60%), head and neck cancers 
(50%) and bladder cancers (45%). High frequencies of 9p21.3 deletions have been documented 
in acute lymphoblastic leukemia ranging from 18% to 45% 1. Moreover, the chromosome 9p21.3 
region adjacent to the loci encoding CDKN2A and CDKN2B is an important susceptibility locus 
for several diseases with a complex genetic background. Recent genome-wide association 
(GWA) studies have shown that single nucleotide polymorphisms (SNPs) in this region are 
associated with coronary artery disease (CAD), ischaemic stroke, aortic aneurysm, type II 
diabetes, glioma, and malignant melanoma. Candidate gene approaches have also reported SNPs 
in this region to be associated with breast, ovarian, and pancreatic carcinoma, melanoma, and 
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acute lymphoblastic leukaemia 44. Most of the risk variants in the chromosome 9p21 region 
identified by GWA studies are in non-coding regions, suggesting that their effects are likely to 
be mediated by influences on gene expression. Sequence variation can influence expression by 
cis or trans mechanisms 45. 
Finally, the human CDKN2A/ARF locus encodes one additional transcript, isoform ‘3’ (p12), and 
perhaps others as well. The p12 transcript represents a p16INK4A-isoform that shares the p16INK4A 
promoter, 5’ UTR, ATG and exon 1α, but then uses an alternative splice donor within the first 
intron of p16INK4A to splice to exon 2. The extra sequence contains a stop codon, and therefore 
the transcript produces a 12 kDa protein that shares the only first ankyrin repeat of p16INK4A. In 
non-diseased tissue, this transcript is only expressed in pancreas but not other human tissues. The 
significance and function of this transcript is unknown, but based on crystal structure studies of 
INK4 proteins, p12 would not be predicted to bind cdk4 or cdk6. Even if the p12 transcript does 
not encode a direct tumor suppressor protein, however, its intimate relationship with the 
INK4A/ARF locus makes it likely that its transcription influences the expression of p16INK4A 
and/or p14ARF 46. 
 
1.4.1 ARF/p14ARF  
1.4.1.1 Gene structure 
The ARF tumor suppressor transcript was first identified in humans in 1995 (p14ARF) 47,48, and its 
protein product confirmed in mice (p19ARF) that same year 49. Its gene locus is on the short arm 
of chromosome 9 in humans, and on a corresponding location on chromosome 4 in mice. ARF is 
an alternate reading frame (ARF) product of the CDKN2A locus. It spans approximately 26 kb of 
genomic DNA and comprise three exons 1β, 2, and 3 (Fig. 1.7). The p14ARF open reading frame 
is derived from a distinct first exon (exon 1β), originating approximately 19 kb centromeric to 
the first exon of p16INK4A (exon 1α) and 23 kb centromeric to exon 2. Exon 1β, under the control 
of its own promoter, is spliced to the second and third exons that are separated by 3 kb of 
intronic sequence and are shared with p16INK4A. The open reading frame of the 1.1 kb ARF 
transcript is terminated within exon 2, with exon 3 comprising an untranslated 3‘ exon. 
 
 
  
Fig. 1.7 ARF NM_058195.3 MapViewer representation.
verse. Blu bars show exons and red bars represent gene translation. Modified from NCBI MapView
http://www.ncbi.nlm.nih.gov/gene/1029#
 
 
1.4.1.2 ARF is a peculiar protein with unusual primary structure 
The human protein comprises 173 amino acids with a molecular weight of 13,902 Da, whereas 
the mouse homologue of 169 amino acids has a molecular weight of 19,238 Da. Both proteins 
share only limited sequence homology (50%) that could explain some of their functional 
differences but both are capable of inducing cell cycle arrest at the G2/M as well
cycle boundaries. The ARF proteins show significant sequence similarity within their amino
terminal 14 amino acids (11/14 identity), and this region retains many of the known ARF 
functions, including nucleolar localization, Mdm2 binding an
The carboxy-terminus of ARF
region (amino acids 130–169) of p19
independent apoptosis. The ability of p14
also involves the C-terminal nucleolar localization sequence of p14
both composed of more than 20% arginine residues conferring them highly basic and 
hydrophobic properties. Interestingly, there
and the protein probably needs to form complexes with other molecules, both to be folded and 
for its charge to be neutralized at physiological pH. This probably explains the increasing 
number of yet identified ARF partners. Mouse 
p14ARF has none. Mouse p19
residues (Met45 and Met48 respectively). Translational initiation from these methionine residues 
produces both in mouse and human a short form of the protein that, when overexpressed, 
localizes to mitochondria (smARF). Nevertheless, full
nucleoli thanks to nucleolar localization signals (NoLS). 
 Green bar shows the length and the gene transcription 
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exon1β (aa 26-37) which deletion induces the nuclear translocation of the protein. The situation 
is more complex for p14ARF as two NoLS have been identified in the protein. The first one 
localized in exon 1β plays a key role in the antiproliferative function of p14ARF as its deletion 
inhibits the ability of p14ARF to stop the cell cycle and to bind Mdm2. The second one stands in 
exon 2 (aa 83-101) and is involved in the ability of p14ARF to promote the sumoylation of its 
binding partners 50. 
1.4.1.3 Expression and turnover 
Expression 
Normal cells contain low levels of ARF but the expression of a variety of proliferation-
promoting proteins, including Myc, E2F, E1A, oncogenic Ras and v-Abl, upregulate ARF as part 
of a checkpoint response conveying on the well known p53-Mdm2 pathway. The discovery of 
multiple ARF interactors and the observation that, aside oncogenic stimuli, also viral, genotoxic, 
hypoxic and oxidative stresses activate an ARF-dependent response, suggest that ARF could 
exert a wider role to protect the cell. It is becoming clear that the ARF response is quite complex 
and is likely accomplished by the interaction with a multitude of different cellular partners that in 
part explain the p53-independent activities of ARF 51. ARF is ubiquitously expressed and is 
elevated in cells lacking p53. In human cells p14ARF expression levels remain low as cells near 
senescence and p14ARF depleted cells still undergo a senescence-like arrest when challenged with 
Ras 46. Not much is known about the regulation of p14ARF expression. p14ARF transcription is 
induced by E2F1, but not by oncogenic Ras and while p14ARF transcription is inhibited by Tbx-2, 
Tbx-3 and Cbx-7, it is not down-regulated by Bmi-1 38,46,52. 
Degradation 
ARF is a relatively stable protein, with half-life estimations ranging from approximately 1–6 h. 
p19ARF and p14ARF undergo amino-terminal ubiquitination and their degradation depends on the 
ubiquitin-proteosome pathway, and may be enhanced by Mdm2 expression. Stress induced 
nucleoplasmic redistribution of ARF destabilises the protein and targeting of a p14ARF fragment 
encompassing amino acids 2–29 to the nucleolus increased its half-life 53. Consistent with these 
data, ARF-B23 complex formation, which restricts ARF to the nucleolus, stabilises ARF by 
blocking its ubiquitination 54. In contrast, Mdm2-ARF complex formation occurs preferentially 
in the nucleoplasm and this may allows for enhanced ARF ubiquitination and proteasomal 
degradation 38. 
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1.4.1.4 Biological functions 
The ARF tumour suppressor is a critical activator of the p53 pathway 
The ARF tumour-suppressor protein suppresses aberrant cell growth in response to oncogene 
activation by inducing the p53-pathway. The ARF induction of p53 is mediated through two 
ubiquitin ligases, Mdm2, a RING finger oncoprotein and ARF-BP1/Mule (ARF-binding protein 
1/Mcl-1 ubiquitin ligase E3), a HECT (homology to E6-AP C-terminus) containing protein. Both 
Mdm2 and ARF-BP1 act as specific E3 ubiquitin ligases for p53, are highly expressed in various 
types of tumours, and have the potential to abrogate the tumour-suppressor functions of p53. 
ARF associates with Mdm2 to inhibit the ubiquitination, nuclear export and subsequent 
degradation of p53. It has been proposed that ARF physically sequesters Mdm2 in nucleoli, thus 
relieving nucleoplasmic p53 from Mdm2-mediated degradation 53. Recent data, however, suggest 
that nucleolar relocalization of Mdm2 is not required for p53 activation and that the 
redistribution of ARF into the nucleoplasm enhances its interaction with Mdm2 and its p53-
dependent growth-suppressive activity 54. This current model of ARF function supports the 
concept that nucleolar disruption contributes to p53 signalling since many stress signals perturb 
the nucleolus, causing the release of nucleolar proteins (including ARF, L5, L11, L23 and B23) 
that activate the p53 pathway. In addition to Mdm2, ARF-BP1 is a key regulator of the p53 cell 
cycle regulatory pathway; ARF-BP1 directly binds and ubiquitinates p53 in an Mdm2-
independent manner. Silencing of ARF-BP1 extended the half-life of p53, resulted in the 
transcriptional activation of the p53 targets, p21Waf1 and BAX, and activated a p53- dependent 
apoptotic response. Unexpectedly, ARF-BP1 also ubiquitinates and promotes the degradation of 
the anti-apoptotic bcl-2 family member, Mcl-1, and down-regulation of ARF-BP1 expression can 
also render cells more resistant to killing by genotoxic agents. Thus, ARF-BP1 has been assigned 
both anti-apoptotic (via p53 degradation) and pro-apoptotic (via Mcl-1 degradation) functions. 
Whilst the effect of ARF on ARF-BP1- mediated Mcl-1 degradation is presently unexplored, the 
divergent roles of ARF-BP1 may be regulated by ARF. Following aberrant oncogene activation, 
ARF expression is induced and inhibits ARF-BP1 activity toward p53 in the nucleus, thereby 
leading to p53-dependent cell cycle arrest or apoptosis. In the cytoplasm, where ARF is not 
abundant, oncogene activation may lead to ARF-BP1 mediated Mcl-1 degradation further 
promoting apoptosis. ARF also enhances p53 function by promoting the phosphorylation and 
inhibiting the transcriptional activity of the RelA NF-kB subunit. The NF-kB family of 
transcription factors display anti-apoptotic activity and antagonise the p53 pathway through 
induction of Mdm2 and repression of p53. Thus, by counteracting the functions of Rel A, ARF 
increases the effectiveness of the p53 pathway 38. 
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Nucleolar functions of the ARF tumour suppressor 
ARF is predominantly a nucleolar protein and rather than residing in inactive “storage” within 
the nucleolus, ARF may regulate ribosome biogenesis by retarding the processing of early 
47S/45S and 32S rRNA precursors 46. These effects do not depend on Mdm2 or p53 but may 
involve the interaction of ARF with B23. B23 is an abundant nucleolar endoribonuclease that is 
required for the maturation of 28S rRNA and interacts with many cellular proteins, including 
p53, Mdm2, ARF, NPM3 and the BARD-BRCA1 ubiquitin ligase. The interaction of ARF and 
B23 retains both proteins in the nucleolus, bound to the pre-60S ribosome, where they appear to 
influence ribosome biogenesis and/or function. The actual role of the nucleolar ARF–B23 
complex remains unclear; p19ARF can promote the ubiquitination and degradation of B23, 
whereas p14ARF had no effect on B23 protein expression. In response to cytotoxic drugs, such as 
actinomycin D and DNA damaging agents, including UV light, B23 and ARF undergoes 
nucleoplasmic redistribution, where Mdm2 and B23 compete for ARF binding. The 
nucleoplasmic translocation of ARF and B23 promotes the formation of the B23-Mdm2 and the 
ARF-Mdm2 binary complexes and induces potent activation of the p53 pathway. Thus, ARF 
may directly access ribosome function to inhibit cell growth through its nucleolar association 
with B23, and it may regulate the p53 cell cycle pathway via its nucleoplasmic interaction with 
Mdm2 and ARF-BP1 38.  
ARF regulates the protein turnover and function of most of its interacting partners 
ARF can also suppress the proliferation of mouse cells lacking both Mdm2 and p53, implying 
interactions with other regulators. Consistent with these findings, the spectrum of tumours seen 
in mice lacking ARF and p53, with or without Mdm2, was significantly greater than that 
associated with animals lacking either gene 38. 
During the last years many efforts have been attempted in search of ARF partners that could 
partly explain the p53-Mdm2 ARF independent functions. In addition to its first ‘‘spouse’’ 
Mdm2, the ARF interactors ‘‘harem’’ consists of something like 30 different proteins involved 
in various cellular activities (Fig. 1.8, Tab. 1.2): proteins involved in transcriptional control, such 
as E2Fs, DP1, c-Myc, p63, Hif1a, Foxm1b, nucleolar proteins such as nucleolin/ C23 and 
nucleophosmin (NPM/B23), viral proteins such as HIV-1Tat, proteins involved in copper 
metabolism like COMMD1, proteins involved in chromosomal stability and/or chromatin 
structure such as Topoisomerase I, Tip60, and WRN helicase, ubiquitin ligases like Ubc9 (the E2 
ligase required for sumoylation), Mdm2 and ARF-BP1/Mule, (E3-ubiquitin ligases) 51. 
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Fig. 1.8 A schematic view of the ‘‘ARF harem’’. ■ Orange is for partners whose activity is blocked by ARF. ■ 
Red is for partners that are induced to proteasome and ubiquitin-dependent degradation by ARF. ■ Pink is for 
partners that are induced to proteasome and ubiquitin-independent degradation by ARF. ■ Green is for partners 
whose activity or stability are positively regulated by ARF. ■ Blue is for partners that regulate ARF protein 
turnover. A second black circle indicate nucleolar sequestration 51. 
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Tab. 1.2 Cellular protein partners of the ARF tumour-suppressor protein, and its biological effect. Modified 
from Stuart J.Gallagher, Int J Biochem Cell Biol, 2006 38. 
 
ARF binding partner Biological effect of ARF binding 
APA-1  No apparent effects 
ARF-BP1/Mule1  Inhibition of ARF-BP1 ubiquitin ligase activity 
B23  Degradation of B23, inhibition of B23 shuttling 
BCL6  Inhibition of BCL6 transcriptional activity 
CARF Enhanced ARF-mediated cell cycle arrest 
c-MYC  Inhibition of c-MYC transactivation 
COMMD1 Poly-ubiquitination of  COMMD1 
CtBP2 Degradation of CtBP2; 
DP-1  Inhibition of ARF-induced E2F proteolysis 
E2F-1, -2, -3  Degradation of E2F 
Foxm1b  Inhibition of Foxm1b transactivation 
HIF-1α  Inhibition of HIF-1α transactivation 
HIV1-Tat protein Ubiquitin-independent degradation of the HIV1-Tat protein 
Mdm2  Inhibition of mdm2 ubiquitin ligase activity 
MdmX  Enhanced p53 transactivation 
Neurabin  Enhanced ARF-mediated cell cycle arrest 
p120E4F  Enhanced ARF-mediated cell cycle arrest 
Pex19p  Inhibition of p19ARF, pex19p does not bind human ARF 
SUMO Conjugation of SUMO to p53 and MDM2 
Tat-binding protein-1  Induces ARF stabilization 
Topoisomerase I  Enhanced topoisomerase I activity 
Ubc9  Probable involvement in p14ARF-mediated sumoylation 
Werners helicase  Nucleolar exclusion of Werners helicase 
 
Although the actual mechanism by which ARF affects the activity of its partners is still unclear, 
the functional consequence is, quite invariably, inactivation.  
For some targets, ARF interaction causes alteration of stability. For example, B23/NPM and E2F 
become degraded by the proteasome in an ubiquitin-dependent manner, while the CtBP2 
antiapoptotic transcriptional co-repressor and HIV-1 Tat become degraded by the proteasome in 
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a ubiquitin-independent manner. Other targets changes their localization like E2Fs, c-Myc, 
Foxm1B, Mdm2, ATR, DP-1, Hif1a upon ARF expression. Only few others, like Tip60, Topo I 
and COMMD1 become activated or stabilized. Finally, most of the partners become sumoylated 
although a precise function to this modification has not yet been assigned.  
Particularly interesting is the inhibitory effect that ARF exerts on oncogenes such as members of 
the E2F family, required both for cell-cycle progression and to mediate ARF oncogenic 
activation, suggesting a potential role of these interactions as being part of a negative feedback 
loop. In a series of reports ARF was shown to interact with E2F1, and this interaction prevented 
the formation of active E2F1 transcritional complexes, inhibited E2F1 transactivation potential, 
and promoted the proteasome-dependent degradation of E2F1, 2 and 3. In line with a role of 
ARF in promoting ubiquitin-dependent degradation of its partners is the observation that 
NPM/B23, an abundant nucleo/nucleolar multifunctional protein involved in ribosome 
biogenesis, is a molecular target of ARF. The vast majority of ARF appears localized in nucleoli, 
tightly associated with NPM/B23. There is a regulative loop between ARF and B23, in which 
degradation and inhibition of both proteins is finely and tightly modulated by external stimuli. In 
such a situation, ARF serves a dual function to restrain both growth and proliferation. 
Interestingly, ARF appears to mediate also ubiquitin-independent degradation like that of the 
antiapoptotic transcriptional co-repressor C-terminal binding protein 2 (CtBP2) and of the HIV1-
Tat protein. Interestingly, Mdm2 has been shown to ubiquitinate HIV1-Tat, although, in this 
case, ubiquitination determines an increase of the Tat-mediated transactivation properties. This 
lead to the speculation that ARF could act on HIV-1Tat in two ways: directly mediating its 
degradation and inhibiting the Mdm2 activity versus Tat, thus blocking viral transcription. This 
hypothesis would intriguingly fit with the ARF role in viral defense. 
As mentioned above, in some cases, ARF is able to stabilize its partners from proteasomal 
degradation. In a quite recent study, it has been described the ARF’s ability to induce a non-
classical poly-ubiquitination of a new interacting partner, the COMMD1 factor, a multifunctional 
protein involved in copper metabolism and apoptosis. While in normal conditions COMMD1 is 
degraded by the proteasome, ARF coexpression leads to a stabilization of the protein through its 
poly-ubiquitination on K63 lysine of the ubiquitin peptide.  
Altogether, although these observations reinforce the idea that the ARF antioncogenic activity 
could be partly exerted through the cellular degradation machinery. In this sense, ARF 
interaction with the proteasome could serve dual roles: on one side it is necessary to regulate 
ARF protein turnover, while, on the other side, it could play a role in bringing ARF interacting 
partners in contact with the ubiquitin/proteasome machinery 51.  
 ARF promotes the sumoylation of its binding partners
ARF can promote the conjugation of the small u
partners, including Mdm2 and B23. Sumoylation is analogous to ubiquitination, and is the 
process by which the SUMO protein is conjugated to a target protein. The effects of this 
modification are target specific a
structures and regulation of transcription factor activities. The diverse functional consequences 
of sumoylation provide a possible explanation for the versatility of ARF downstream effects. 
Although, ARF can promote sumoylation in 
not been demonstrated for ARF binding partners and sumoylation sites on these proteins remain 
unidentified. However, the fact that a subset of melanoma
sumoylate Mdm2 in vivo, suggests that sumoylation may provide a mechanism for the diverse 
actions of the ARF tumour-suppressor protein
 
1.4.2 CDKN2A/INK4A/p16INK4A 
CDKN2A (cyclin dependent 
dependent Kinase 4 (INK4) family of proteins which also includes p15
p19INK4D. The INK4 proteins are roughly 40% homologous to one another, but individual 
members are highly conserved across species. Family members have in common a 
structural motif: a series of ankyrin repeats responsible for interaction with cyclin
kinases 4/6 (CDK4/6). CDKN2A
by three exons: 1α, 2 and 3 (Fig.
 
Fig. 1.9 CDKN2A NM_000077.4 MapViewer representation
transcription verse. Blu bars show exons and red bars represent gene translation. Modified from NCBI MapViewer 
http://www.ncbi.nlm.nih.gov/gene/1029
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 The human protein comprises 156 amino acids with a molecular weight of ~15.8kD. Its structure 
consists of repeated ‘ankyrin’ subunits containing two antiparallel helices and a loop, creating a 
cleft that binds CDK4 or CDK6
each β-hairpin loop are exposed to the cdk binding site; helix 2 and some loop residues provide 
structural support (Fig. 1.10) 55
 
Fig. 1.10 Structural models of p16
the right) of the p16 structure, while 
b show in purple the aminoacids in the binding cleft that contact CDK6. In 
ribbon, and the molecule is viewed down the axis of the cleft. Modified from
 
CDKN2A expression levels are low in normal tissue. Following controversy concerning the 
cellular localization of p16 it has recently been shown that p16 can be expressed in both the 
nuclear and cytoplasmic compartments and that both nuclear and cytoplasmic p16 forms 
complexes with CDK4 and CDK6
appears predominantly in just one. p16 is upregulated in cells during in 
consistent with a role in ageing. Expression of p16 is often lost during progressi
INK4 binding to CDK4/6 inhibits its kinase activity and thereby arrests progression through the 
cell cycle in mid-late G1 (Fig
association with CDK4/6, shifting the CDK4/6 k
instead of active complexes with cyclin D. Inhibition of CDK4/6 kinase activity prevents pRB 
phosphorylation leading to restraint of E2F transactivation of the expression of genes important 
. The first helix of each pair and the last several aminoacids of 
. 
 
 
. Images a, on the left shows the front (binding cleft, helices to the left, loops to 
b, on the right, shows the back (helices to the right) of the p16 structure.
b, the p16 backbone is rendered as a 
 M S Greenblatt, Oncogene, 2003
. Cytoplasmic p16 occurs in two forms whilst nuclear p16 
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Fig. 1.11 p16INK4A /pRB pathways. p16
that phosphorylate, and therefore inactivate, RB during the mid
Hyperphosphorylated pRB dissociates from E2F1 trancription factor enabling transcription of S
as myc, as well as ARF.  
 
In the absence of pRB, forced induction of p16 does 
many tumors that retain p16 expression, especially gliomas, other alterations occur in the p16
cyclinD-CDK4-pRB pathway: loss of pRB expression or overexpression of CDK4 or cyclin D1. 
A negative feedback loop exists between pRB and p16: transcription of 
Therefore, it is not surprising that cells with inactive pRB frequently have elevated levels of 
expression, although in this setting p16 becomes ineffective in
According to repository data into
(https://biodesktop.uvm.edu/perl/p16
the majority of mutations identified so far in 
mutations affect either p16 alone or both p16 and 
1.11). The expression of pRB is essential for transducing p16’s 
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 inhibits the complex between cyclin-dependent kinase 4/6 and cyclin D 
-late G1 phase of the cell cycle. 
not cause cell cycle arrest. As a result, in 
p16
 restraining cell prolife
 UVM BioDesktop-CDKN2a Database Project
 and http://atlasgeneticsoncology.org/Genes/CDKN2aID146.html
CDKN2A are located in exons 1a and 2. These 
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 susceptibility to melanoma. A small number of mutations have been identified in exon 1b which 
appear to affect p14ARF alone. 
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deletion affecting the p14ARF 
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1.4.3 CDKN2B/INK4B/p15INK4
CDKN2B (cyclin-dependent kinase inhibitor 2B)
CDKN2A in a region that is frequently mutated and deleted in a wide variety o
gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, 
and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell 
growth regulator that controls cell cycle G1 progression.
to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced 
growth inhibition. Two alternatively spliced transcript variants of this gene, which encode 
distinct proteins, have been reporte
when compared to longer isoform.
 
Fig. 1.12 CDKN2B MapViewer representation
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CDKN2A locus have been described for a number of 
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p14ARF function alone may be the key factor in this family. 
mutations of CDKN2A are found in approximately 24% of 
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The human protein (the longer one) comprises 138 amino acids with a molecular weight of 
14,722 Da; like CDKN2A has a basic structural motif of a series of four ankyrin repeats 
responsible for protein–protein interactions. 
Whereas the tumour suppressor functions for CDKN2A and ARF have been firmly established, 
the role of CDKN2B remains ambiguous. However, many 9p21 deletions also remove CDKN2B, 
so we hypothesized a synergistic effect of the combined deficiency for CDKN2B, ARF and 
CDKN2A 57. 
In leukemias, the CDKN2B gene is commonly inactivated in association with promoter region 
hypermethylation involving multiple sites in a 5'-CpG island, whereas point mutations are rare 
58
. Hypermethylation of the CDKN2B gene was more frequent in cases with T-cell origin ALL 
(46.2%), but similar among children with B-cell origin ALL (13.0%) and AML (18.8%). 
Hypermethylation of CDKN2B may be involved in the pathogenesis of T-cell origin ALL, but 
not in that of AML or B-cell origin ALL 59. 
1.4.4 ANRIL/CDKN2BAS (CDKN2B-AS1 CDKN2B antisense RNA 1) 
In the 9p21 locus overlaps a newly annotated non-coding RNA (ncRNA), termed ANRIL, for 
‘‘antisense noncoding RNA in the INK4 locus’’. ANRIL spans 126.3 kb, with a first exon located 
in the promoter of the ARF gene and overlapping at its 5‘ end the two exons of CDKN2B. It 
consists of 20 exons subjected to alternative splicing, that are transcribed in the anti-sense 
orientation (Fig. 1.13).  
 
 
Fig. 1.13 A genomic organization of the 9p21 gene cluster. Boxes, location of exons (approximately to scale). 
Exons 1α, 2, and 3 of CDKN2A encode p16 protein, whereas exon 1β, spliced to exons 2 and 3of CDKN2A in a 
different reading frame and transcribed using a different promoter, encodes p14ARF protein. The ANRIL gene 
overlaps the two exons of CDKN2B and is transcribed in the orientation opposite to the CDKN2B-CDKN2A-ARF 
gene cluster. Exon 1 of ANRIL is present about 300 bp upstream of the transcription start site of ARF (exon 1β) 60. 
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Up to now three ANRIL variants were identified. Full-length ANRIL (3834 bp), deposited under 
GenBank accession number DQ485353, encompasses the first 12 exons plus exons 14 to 20. At 
least 2 shorter variants of ANRIL that end with an alternative exon 13 have been reported, 
DQ485454 and EU741058. DQ485454 (2659 bp) comprises the first 12 exons and an alternative 
exon 13, whereas EU741058 (688 bp) encompasses exons 1, 5 to 7, and 13 (Fig. 1.14).  
 
 
 
Fig. 1.14 Physical Map of the 9p21.3 region. ANRIL produces alternative transcripts DQ485453, DQ485454, and 
EU741058. Modified from Olga Jarinova, Arterioscler Thromb Vasc Biol, 2009 61. 
 
Exon sequences of ANRIL are highly conserved in primates, furthermore, several exons of 
ANRIL retain repetitive elements and encompasses multiple binding sites for transcription factors 
that regulate transcriptional repression. Thus, exons 7 and 12 of ANRIL consist entirely of Alu 
repeats; exons 8 and 16 of Long Terminal Repeats (LTRs); exon 14 of the LINE2 element (long 
interdispersed elements), and exons 4, 17, and 20 contain multiple MIR SINEs (short 
interdispersed elements). The presence of repetitive elements within the ANRIL gene is 
surprising because low complexity DNA sequences are not usually found within coding regions. 
A recent study suggests that the presence of repetitive elements is a common signature for novel 
genes originated from retroposition and exon shuffling, and degeneration of such elements is 
correlated with the increasing ages of the genes. Thus, ANRIL may have arisen relatively 
recently in mammalian evolution before the divergence of the primate lineage and may possess 
novel primate-specific functions. Alternatively, low sequence conservation of ANRIL may reflect 
high rates of primary sequence evolution suggested for long ncRNAs. 
Tumour suppressor genes (TSGs) inhibiting normal cellular growth are frequently silenced 
epigenetically in cancer. DNA methylation is commonly associated with TSG silencing, yet 
mutations in the DNA methylation initiation and recognition machinery in carcinogenesis are 
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unknown. An intriguing possible mechanism for gene regulation involves widespread non-
coding RNAs such as microRNA, Piwi-interacting RNA and antisense RNAs. Widespread 
sense-antisense transcripts have been systematically identified in mammalian cells, and global 
transcriptome analysis shows that up to 70% of transcripts have antisense partners and that 
perturbation of antisense RNA can alter the expression of the sense gene. Therefore, noncoding 
RNAs such as ANRIL can alter expression of associated protein coding genes through multiple 
mechanisms that include RNA interference, gene silencing, chromatin remodeling, gene co-
suppression, imprinting, or DNA methylation. There is growing evidence of involvement of 
ncRNAs transcribed from the 9p21 locus in disease etiology. A natural p15 antisense, p15AS, 
triggers transcriptional silencing in cis and in trans of p15 through heterochromatin formation 
but not DNA methylation and shows increased levels of expression in acute myeloid leukemia 
cell lines; in addition the silencing persisted after p15AS was turned off, although methylation 
and heterochromatin inhibitors reversed this process 62. Broadbent and colleagues have 
demonstrated that ANRIL is expressed in many cell types known to be affected by atherosclerosis 
and suggested that this gene is a possible candidate gene at the 9p21 CAD risk locus 63. Jarinova 
et al. examined the structure and function of 4 conserved noncoding sequences (CNS) present in 
the 9p21.3 locus and demonstrated that the CNS3 regulatory region acts as an enhancer and 
significantly increases reporter gene expression. This regulatory activity is attributable to the 
presence of a single nucleotide polymorphism, rs1333045, in strong LD with representative 
SNPs of the previously defined 9p21.3 risk region. They also found that CDKN2B may be 
directly affected by alterations in ANRIL expression related to the 9p21.3 risk haplotype 61. 
Despite the potential importance of ANRIL, limited information is available on its genetic 
architecture. 
Moreover, it cannot rule out the possibility that ANRIL gene could be able to produce mature 
miRNAs or encode a small peptide. Additional studies are thus necessary to elucidate the 
putative role via a genetic (or epigenetic) mechanism of ANRIL gene on the regulation 
(deregulation in tumorigenesis) of the p15/CDKN2B-p16/CDKN2Ap14/ARF locus 60. 
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1.5 CDKN2A LOCUS ALTERATIONS  
Genetic alterations including chromosomal translocation, promoter hypermethylation, somatic 
mutation, and gene deletion are thought to play a key role in oncogenesis. Alterations of the 
9p21 locus have been implicated in many types of cancer, indicating a role for the tumor 
suppressor genes CDKN2A/ARF and CDKN2B. Loss of cell proliferation control and regulation 
of the cell cycle are known to be critical to cancer development. It has been reported that 
CDKN2A and CDKN2B are frequently inactivated in various hematologic malignancies 64. The 
mechanism of CDKN2A/ARF inactivation in human cancers is somewhat tumor specific. 
Homozygous deletions at CDKN2A/9p21 are common in bladder tumors and have been 
described in a variety of other sporadic tumors, including melanomas and gliomas. Pancreatic 
adenocarcinomas show inactivation of CDKN2A by either homozygous deletion or point 
mutation, whereas esophageal tumors commonly show inactivation by point mutation. A third 
mechanism of inactivation, transcriptional silencing by promoter hypermethylation, is commonly 
found in colorectal carcinoma. Point mutations have only rarely been identified in bladder 
tumors and promoter methylation, only infrequently 39. 
An excellent 1998 review (Drexler, 1998) summarized the alterations of the INK4 family 
members in leukemias of primary samples and cell lines 65. Most alterations occur by 
inactivation of CDKN2A and CDKN2B due to hypermethylation of CpG islands in their 
promoters or by deletions in the 9p21 region, frequently involving all three genes. A high 
frequency of hypermethylation of the CDKN2B promoter occurs in AML (79%) including acute 
promyelocytic leukemia (APL) (73%) and MDS (42%). T-ALL and Pre-B-ALL cells often have 
hypermethylation of the CDKN2B promoter (44%) and deletions of the CDKN2A (33%) and the 
CDKN2B (32%) genes 66. 
Inactivation of CDKN2A and CDKN2B is primarily a consequence of mono- or biallelic 9p21.3 
deletion rather than promoter methylation or mutations 67. 
In fact, the chromosomal region of 9p is a frequent site of loss or deletion in several human 
cancers, lung cancer, esophageal cancer, melanoma, in glioma (60%), head and neck cancers 
(50%) and bladder cancers (45%) 68. Homozygous deletion of CDKN2A has been suggested as 
the dominant mechanism of its inactivation in leukemogenesis 64. High frequencies of 9p21.3 
deletions have been documented also in acute lymphoblastic leukemia ranging from 18% to 45% 
69-79,1
. 
The majority of human tumors with homozygous deletion of this genomic region have large 
deletions of the whole CDKN2A/ARF locus often including the gene encoding p15 (CDKN2B) 39. 
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A majority of interstitial deletions in lymphoid leukemia have been indicated to be mediated by 
illegitimate V(D)J recombination between two ectopic heptamer-recombination signal sequences 
(RSS) sites in the 9p21 segment, where DNA double-strand breaks (DSBs) trigger 9p21 
deletions at no specific DNA sequences, although they preferentially occur in or near the 
CDKN2A locus. At present, nucleotide sequences susceptible to DSBs in the CDKN2A locus 
remain unclear. Interestingly, recent studies have indicated that the packaging structure of 
chromatin affects the susceptibility to several DNA damaging agents. Thus, it is also possible 
that the open chromatin structure associated with the CDKN2A gene expression rather than 
nucleotide sequences might be responsible for susceptibility to DSBs 80. 
CDKN2A and CDKN2B deletions might be also initiated by ‘off-target’ effects of the lymphoid 
mutagenic enzymes Recombination Activating proteins 1 and 2 (RAG1 and RAG2) or 
activation-induced cytidine deaminase (AID). 
Therefore, another possibility is that the association between increased risk of ALL and inherited 
variation in CDKN2A and CDKN2B reflects its structural or sequence-based vulnerability as a 
substrate 67. 
In ALL patient samples, the size and position of 9p21.3 deletions seem to vary substantially, but 
in most cases CDKN2A is co-deleted with CDKN2B and MTAP (methylthioadenosine 
phosphorylase) 77,79,1. The frequence of genomic deletions is of 21% in B-cell precursor ALL 
and 50% in T-ALL patients 1.  
In childhood ALL, the reported frequencies of both heterozygous and homozygous deletions 
vary, 9% to 27% and 6% to 33% in B-cell precursor (BCP) ALL and 7% to 18% and 30% to 
83% in T-ALL, respectively64. Sulong et al. (2009) demonstrated that genomic deletion of 
CDKN2A is substantially more prevalent in childhood ALL (20% in BCP-ALL and 50% in T-
ALL) than either mutation or methylation. They concluded that genomic deletion is the principal 
mode of CDKN2A inactivation in childhood ALL. In agreement with previous large studies 
1,77,81
, they found that the incidence of CDKN2A deletions was significantly higher among T-
ALL patients compared with BCP-ALL patients, which included the proportion of biallelic 
deletions. Among BCP-ALL patients, they found a frequency of CDKN2A deletions of 21%, 
which was the same as Kawamata et al. 82 (21%) but lower than Bertin et al. 77 (31%), Usvasalo 
et al. 1 (46%) and Mullighan et al. 81 (34%). They also found that 50% T-ALL harbored a 
CDKN2A deletion, a frequency substantially lower than that reported by Bertin et al. 77(78%), 
Mullighan et al. 81 (72%), and Kawamata et al. 82(78%) 64. 
Compared with childhood, adult ALL deletions characterization in the 9p21 chromosomic band 
were less studied. Paulsson K. et al (2008) found CDKN2A deletions in the 47% of the cases. 
40 
 
Their findings in adult ALL are strikingly similar to what has recently been reported in pediatric 
ALL. Mullighan et al. 81 detected deletions of CDKN2A in a high proportion of childhood cases; 
a finding that was subsequently confirmed by Kuiper et al. 81. Kawamata et al. 82 also reported 
frequent CDKN2A deletions in pediatric cases, although they used a different sampling 
populations or differing analytical methods. The similarity between childhood and adult ALL as 
regards CDKN2A deletions was unexpected considering that the cytogenetic patterns of these 
disease entities are quite different; in particular, adult ALLs display a higher frequency of 
t(9;22)-positive cases but virtually lack the most common pediatric abnormalities, t(12;21) and 
high hyperdiploidy. It is thus possible that microdeletions in comparison may play a more 
general leukemia-promoting role and may be shared among different clinical, morphological and 
cytogenetic subgroups of ALL 83. 
In addition to deletions, the CDKN2A locus can also be inactivated by epigenetic silencing 
through DNA methylation of the CpG islands associated with their respective or by point 
mutations, both resulting in gene silencing . Methylation of CDKN2A and CDKN2B (frequencies 
of 6% and 57%, respectively) seems to lack prognostic significance in ALL 84, and the rate of 
point mutations has been extremely low in ALL 1,78,85-89. 
The frequency of hypermethylation of the CDKN2A promoter has been reported to vary from 0 
to 40% in childhood ALL 90-94. As reported data on CDKN2A alterations in childhood ALL are 
discrepant, it remains important to reveal the role of this gene in cancer development. CDKN2A 
hypermethylation is not a disease-specific event because it has been observed in the mononuclear 
cells from normal participants 64. 
Mutation or methylation was rare, whereas genomic deletion occurred in 21% of B-cell 
precursor ALL and 50% of T-ALL patients 1. 
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1.6 SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) IN 9p21 LOCUS  
Until recently, little was known about alterations of cyclin dependent kinase inhibitors CDKN2B, 
CDKN2A and ARF due to SNPs located within the CDKN2A/B genes and/or neighboring loci, 
but in the last few years studies aimed to investigate the potential involvement of such common 
DNA sequence variants in tumour susceptibility increased. 
For example Brian G.K. et al. published (Jan-2011) a study on a 58 kb region on chromosome 
9p21.3 which consistently showed a strong association with coronary artery disease in multiple 
genome-wide association analyses in populations of European and East Asian ancestry. In this 
study, they characterized the role of genetic variants in 9p21.3 in African American individuals. 
Apparently healthy African American siblings of patients with documented CAD <60 years of 
age were genotyped and followed for incident CAD for up to 17 years. The findings 
demonstrated a significant protective effect of single SNP within the CDKN2B gene, rs3217989, 
against incident CAD in African American siblings of persons with premature CAD 95. 
Also the rs10811661 polymorphism near the CDKN2B/CDKN2A genes was associated with 
impaired insulin release and impaired glucose tolerance (IGT), suggesting that this variant may 
contribute to type 2 diabetes by affecting β-cell function 96. 
The locus 9p21.3 variants associate with multiple disease phenotypes CAD, type 2 diabetes 
mellitus (T2DM), ischemic stroke, and abdominal aortic aneurysm 97,48, breast, ovarian, 
pancreatic carcinoma, melanoma, and acute lymphoblastic leukaemia 44. Variants associated with 
these diseases are represented in Figure 1.15 97,45. 
Nature Genetics published, on June 2010, a study showing that a common variation at 9p21.3 
influences acute lymphoblastic pediatric leukemia risk. This SNP is the rs3731217, located in the 
intron between 1β and 1α of CDKN2A/ARF (Chr9: 21,974,661 base pairs; within a 174-kb region 
of linkage disequilibrium at 9p21.3) 67. 
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Fig. 1.15 SNPs associated with disease in the chromosome 9p21.3 region. Genes are illustrated in blue at the top, 
with arrows representing the direction of transcription. SNPs associated with various diseases are represented by 
black bars. Diseases in bold are those with association data from genomewide association studies. The hatched box 
represents the core risk haplotype for CAD defined by Broadbent et al 63. Promoter regions for each gene are shown 
as pale blue boxes. DM= diabetes mellitus type II; BCC = basal cell carcinoma. 
doi:10.1371/journal.pgen.1000899.g001 45. 
 
Our laboratory (manuscript in press) performed a case-control association study by genotyping 
23 SNPs spanning the MTAP, CDKN2A/B and CDKN2BAS loci, as well as relative intergenic 
regions, in a case-control cohort made up of 149 leukemia patients, including Ph+ acute 
lymphoblastic leukemia and AML samples, and 183 healthy controls. We found, among these 
genetic variations, a statistically significant association between a common ANRIL genetic 
variant, rs564398, mapping to the CDKN2BAS locus that encodes for ANRIL, and the ALL 
phenotype. This probably reflects a condition of high linkage disequilibrium between such 
polymorphism and a causative variant that is able to alter 3 CDKN2A/B expression profiles, thus 
leading to abnormal proliferative boosts and consequent increased ALL susceptibility.  
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1.7 PROGNOSTIC SIGNIFICANCE OF 9p21 INACTIVATION  
The prognosis of B-lineage acute lymphoblastic leukemia (B-ALL) of children is significantly 
superior to that of adults 98,99. The difference in prognosis has been attributed to a differing 
incidence in genetic changes that determine the prognosis, such as the presence of the 
Philadelphia chromosome, ETV6/RUNX1 (formerly TEL/AML1) abnormality, MLL gene 
rearrangement, and ploidy changes. Nonetheless, the prognostic disparity between childhood and 
adult B-ALL is not fully explained by these genotypic differences, suggesting a role of other 
factors in the clinical behavior of B-ALL. 
The silencing of the 9p21 gene cluster is thought to be one of the factors that cause a difference 
in the outcome 69,98-100. The band is identified like one of the major aberration hot spots in human 
cancers 99,100.  
Many studies have been performed on the deletion or methylation patterns of CDKN2A, ARF and 
CDKN2B and their prognostic significance in ALL 98,101,102. Most studies, however, have been 
limited by a small study cohort, leading to uncertain statistical significance, a lack of concurrent 
deletion and methylation profiles, and a lack of comparison between adult and childhood B-
ALL.  
The interesting study on the pattern of deletion and methylation status of the CDKN2A, ARF and 
CDKN2B genes in the context of established prognostic cytogenetic changes in childhood and 
adult B-ALL, of Kim M. et al. (2009) suggest that (a) homozygous deletion occurs more 
frequently in adults than in children; (b) homozygous deletion affects OS only in adult B-ALL; 
(c) homozygous deletion, but not hemizygous deletion, has prognostic effect; and (d) 
methylation of p16, p14, and p15 does not affect the survival of B-ALL patients 103. 
One thing that might explain the higher prevalence of homozygous deletion in adults than in 
children is cellular senescence, which increases with aging. Because the deletion of a gene 
results from faulty DNA replication, the homozygous deletion of tumor suppressor genes, which 
is a cumulative consequence of hemizygous deletion, could be associated with cell senescence. 
Why homozygous deletion has little effect on survival in children is unclear. Other good 
prognostic factors or other oncogene alterations that were not investigated in that study might 
have prevented or weakened the negative effects of homozygous 9p21 deletion on disease 
progression. 
The prognostic significance was limited to homozygous deletion of 9p21, which could be 
explained by loss of heterozygosity 65. Unlike homozygous deletion, hemizygous deletion might 
not be sufficient to turn off the function of these genes. Another explanation could be the high 
genomic instability in leukemia. Genomic instability, evidenced by the increased frequency of 
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cytogenetic, genetic, and epigenetic alterations, is a prominent hallmark of neoplastic evolution 
and tumor progression. Homozygous deletion of CDKN2A, ARF and CDKN2B might reflect the 
disease progression of B-ALL, for which the prognosis is worse than B-ALL with hemizygous 
deletion of CDKN2A, ARF and CDKN2B 103. 
As regards the prognostic relevance of CDKN2A deletions exclusively in childhood ALL, the 
literature is divided, with some studies have suggested that CDKN2A deletion is a poor 
prognostic factor 69,70,72,101,104,105, whereas others show no correlation 74,76,100. Beyond, Usvasalo 
et al. didn’t observe any difference in the incidence of CDKN2A deletion between diagnosis and 
relapse 64. 
The prognostic significance of methylation of the CDKN2A, ARF and CDKN2B genes is also 
controversial and differs in several studies. The level of gene expression might be controlled by 
the extent of methylation, rather than by methylation itself, and thus further clarification requires 
the quantitation of methylation of CDKN2A, ARF and CDKN2B using pyrosequencing or 
methylation sequencing analysis 103. 
Although studied by several groups, the prognostic value of CDKN2A deletion in ALL remains 
uncertain, as summarized in the two tables below (Tab. 1.3 and 1.4). 
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Table 1.3 and 1.4 Prognostic relevance of CDKN2A/ARF (p16, p14) and CDKN2B (p15) alterations (summary of 
literature). Highlighted paper title refers to childhood (■) and adult (■) study. 
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Author Title Journal Year 
Kim M. et al. 
103
 
Homozygous deletion of CDKN2A (p16, p14) and CDKN2B 
(p15) genes is a poor prognostic factor in adult but not in 
childhood B-lineage acute lymphoblastic leukemia: a 
comparative deletion and hypermethylation study.(*) 
Cancer Genet 
Cytogenet 
2009 
Papadhimitriou 
SI. et al.
106
 
p16 inactivation associated with aggressive clinical course and 
fatal outcome in TEL/AML1-positive acute lymphoblastic 
leukemia. 
J Pediatr 
Hematol 
Oncol. 
2005 
Primo D. et 
al.
102
 
Genetic heterogeneity of BCR/ABL
+
 adult B-cell precursor 
acute lymphoblastic leukemia: impact on the clinical, 
biological and immunophenotypical disease characteristics. 
Leukemia 2005 
Dalle JH. et 
al.
107
 
p16(INK4a) immunocytochemical analysis is an independent 
prognostic factor in childhood acute lymphoblastic leukemia.  
Blood 2002 
Calero Moreno 
TM. et al.
70
 
Deletion of the Ink4-locus (the p16ink4a, p14ARF and 
p15ink4b genes) predicts relapse in children with ALL treated 
according to the Nordic protocols NOPHO-86 and NOPHO-92. 
Leukemia 2002 
Hoshino K. et 
al.
108
 
The absence of the p15INK4B gene alterations in adult 
patients with precursor B-cell acute lymphoblastic leukaemia 
is a favourable prognostic factor. 
Br J Haematol 2002 
Carter TL. et 
al.
101
 
Hemizygous p16(INK4A) deletion in pediatric acute 
lymphoblastic leukemia predicts independent risk of relapse.  
Blood 2001 
Ramakers-van 
Woerden NL. 
et al.
109
 
In vitro drug resistance and prognostic impact of 
p16INK4A/P15INK4B deletions in childhood T-cell acute 
lymphoblastic leukaemia 
Br J Haematol 2001 
Heerema NA. 
et al.
105
 
Association of chromosome arm 9p abnormalities with 
adverse risk in childhood acute lymphoblastic leukemia: a 
report from the Children’s Cancer Group.  
Blood 1999 
Moreno TC et 
al.
110
 
Inverse correlation between Ink4-locus deletions and ICM-
DNA hyperdiploidy in childhood acute lymphoblastic 
leukaemia, relation to clinical characteristics and outcome 
Eur J 
Haematol. 
2000 
Kees UR. et 
al.
69
 
Homozygous deletion of the p16/MTS1 gene in pediatric 
acute lymphoblastic leukemia is associated with unfavorable 
clinical outcome.  
Blood 1997 
Zhou M. et 
al.
111
 
Incidence and clinical significance of CDKN2/MTS1/P16ink4A 
and MTS2/P15ink4B gene deletions in childhood acute 
lymphoblastic leukemia.  
Pediatr 
Hematol 
Oncol 
1997 
Heyman M. et 
al.
72
 
Prognostic importance of p15INK4B and p16INK4 gene 
inactivation in childhood acute lymphocytic leukemia. 
J Clin Oncol 1996 
Heyman M. et 
al.
112
 
Inactivation of thep15INKB and p16INK4 genes in hematologic 
malignancies. 
Leuk 
Lymphoma 
1996 
Fizzotti M. et 
al.
104
 
Detection of homozygous deletions of the cyclin-dependent 
kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia 
and association with adverse prognostic features. 
Blood 1995 
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Sulong S. et 
al. 64 
A comprehensive analysis of the CDKN2A gene in childhood 
acute lymphoblastic leukemia reveals genomic deletion, copy 
number neutral loss of heterozygosity, and association with 
specific cytogenetic subgroups. 
Blood 2009 
Uvasalo A. et 
al. 
1
 
CDKN2A deletions in acute lymphoblastic leukemia of 
adolescents and young adults: an array CGH study. 
Leuk Res 2008 
Mirebeau D. 
et al.
74
 
The prognostic significance of CDKN2A, CDKN2B and MTAP 
inactivation in B-lineage acute lymphoblastic leukemia of 
childhood. Results of the EORTC studies 58881 and 58951. 
Haematologica 2006 
L.J. van 
Zutven et al.
76
 
CDKN2 deletions have no prognostic value in childhood 
precursor-B acute lymphoblastic leukaemia. 
Leukemia 2005 
Cipollotti R. et 
al.
113
 
Inactivation of the p15 gene in children with acute 
lymphoblastic leukemia. 
Sao Paulo Med 
J 
2003 
Manero G.G. 
et al.
99
 
Aberrant DNA methylation in pediatric patients with acute 
lymphocytic leukemia 
Cancer 2003 
Manero G.G. 
et al.
98
 
DNA methylation of multiple promoter-associated CpG islands 
in adult acute lymphocytic leukemia 
Clin Cancer 
Res 
2002 
Graf Einsiedel 
H. et al
100
 
Deletion analysis of p16INKa and p15INKb in relapsed 
childhood acute lymphoblastic leukemia. 
Blood 2002 
Graf Einsiedel 
H. et al.
114
 
Prognostic value of p16(INK4a) gene deletions in pediatric 
acute lymphoblastic leukemia.  
Blood 2001 
Chim CS. et 
al.
84
 
Methylation of p15 and p16 genes in adult acute leukemia: 
lack of prognostic significance. 
Cancer 2001 
Faderl S. et 
al.
115
 
The prognostic significance of p16INK4a/p14ARF and 
p15INK4b deletions in adult acute lymphoblastic leukemia. 
Clin Cancer 
Res 
1999 
Rubnitz JE. et 
al.
116
 
Genetic studies of childhood acute lymphoblastic leukemia 
with emphasis on p16, MLL, and ETV6 gene abnormalities: 
results of St Jude Total Therapy Study XII. 
Leukemia 1997 
Dicianni MB 
et al.
117
 
Shortened survival after relapse in T-cell acute lymphoblastic 
leukemia patients with p16/p15 deletions. 
Leuk Res 1997 
Batova A. et 
al.
118
 
Frequent deletion in the methylthioadenosine phosphorylase 
gene in T-cell acute lymphoblastic leukemia: strategies for 
enzyme-targeted therapy.  
Blood 1996 
Ohnishi H. et 
al.
78
 
Homozygous deletions of p16/MTS1 and p15/MTS2 genes are 
frequent in t(1;19)-negative, but not in t(1;19)-positive B 
precursor acute lymphoblastic leukemia in childhood. 
Leukemia 1996 
Okuda T. et 
al.
119
 
Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in 
pediatric acute lymphoblastic leukemia.  
Blood 1995 
Stock W. et al. 
High incidence of p16 deletion in adult acute lymphoblastic 
leukemia (ALL): correlation with clinical features and response 
to treatment: CALGB 8762. 
Blood 1995 
Takeuchi S. et 
al.
88
 
Analysis of a family of cyclin-dependent kinase inhibitors: 
p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute 
lymphoblastic leukemia of childhood. 
Blood 1995 
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1.8 TREATMENT OF PH+ ACUTE LYMPHOBLASTIC LEUKEMIA  
Until recently, Ph+ ALL carried a dismal prognosis in both children and adults. Patients with 
Ph+ ALL who received conventional chemotherapy reportedly had long-term survival rates of 
approximately 10%, and only allogeneic stem cell transplantation (alloSCT) extended long-term 
survival in 38% to 65% of patients. Outcomes for patients with Ph+ ALL improved substantially 
with the introduction of the tyrosine kinase inhibitor (TKI) imatinib mesylate. Although imatinib 
monotherapy in previously treated patients with Ph+ ALL produced only a modest, short-lived 
response, imatinib combined with chemotherapeutic regimens has induced complete remissions 
(CRs) in almost every patient (~95%) with newly diagnosed Ph+ ALL. However, imatinib 
resistance develops in a substantial proportion of imatinib-treated patients with Ph+ ALL. About 
50–80% of the Ph+ ALL patients who achieved a CR with imatinib relapse within 1 year, mainly 
due to the emergence of Bcr-Abl kinase domain point mutations, which impair imatinib binding 
either by affecting critical contact residues or by inducing a Bcr-Abl conformation to which 
imatinib is unable to bind. Second-generation TKIs (eg, dasatinib and nilotinib) have 
demonstrated promising efficacy in the treatment of imatinib-resistant, Ph+ ALL 2,34. 
1.8.1 Standard chemotherapy and allogeneic stem cell transplantation (alloSCT) 
Although CRs may occur in 70% to 90% of patients with Ph+ ALL who receive intensive 
chemotherapy alone, most patients relapse and die within 6 to 11 months of treatment. AlloSCT 
substantially improves long-term survival rates. Several factors influence the outcome of patients 
who undergo alloSCT. Patients who underwent alloSCT during first CR had substantially better 
outcomes than patients who underwent alloSCT in second or later CR. Other favorable factors 
include younger age, total body irradiation conditioning, the use of a human leukocyte antigen-
identical sibling donor, and the occurrence of acute graft-versus-host disease. The widespread 
use of alloSCT often is hindered by donor availability. This limitation has been overcome in part 
by the use of unrelated donors, nonmyeloablative conditioning regimens to facilitate the 
extension of eligibility for SCT, and harvesting stem cells from umbilical cord blood. 
Nevertheless, approximately 30% of patients who undergo SCT relapse, and treatment-related 
mortality (up to 40%) is a frequent cause of failure. The role of TKIs after alloSCT is discussed 
below. In summary, improved therapies for patients with Ph+ ALL are still needed 2. 
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1.8.2 Tyrosine kinase inhibitors 
1.8.2.1 Imatinib mesylate. (Gleevec, Glivec; STI571) 
The first BCR-ABL inhibitor to gain clinical approval was imatinib mesylate, which partially 
blocks the adenosine triphosphate (ATP) binding site of BCR-ABL, preventing a conformational 
switch of the oncogenic protein to the activated form. Early studies demonstrated that many 
patients with previously treated, Ph+ ALL initially responded to imatinib monotherapy with CR 
rates of 20% then but quickly relapsed after a median treatment duration of 58 days. Thus, 
although imatinib was well tolerated and produced a modest response in patients with previously 
treated, Ph+ ALL when it was used as single-agent therapy, responses were short-lived, and 
relapses were common. 
Imatinib resistance has been attributed to BCR-ABL-dependent and BCR-ABL-independent 
mechanisms. BCR-ABL-dependent mechanisms include amplification of the BCR-ABL gene 
and mutations within ABL that reactivate BCR-ABL and disrupt binding to the drug 
target.Indeed, more than 90 separate resistance conferring point mutations at 57 residues in the 
Abl kinase have been documented, and these generally fall within four regions of the kinase 
domain: the ATP-binding pocket (P-loop), the contact site (eg, threonine at codon 315 [T315] 
and phenylalanine at codon 317 [F317]), the Src homology 2 (SH2)  binding site (eg, methionine 
at codon 351 [M351]) and the activation loop (A-loop). A common mutation that occurs 
frequently after imatinib therapy in Ph+ ALL patients is the glutamic acid to lysine mutation at 
codon 255 (E255K). P-loop mutations are 70-fold to 200-fold less sensitive to imatinib 
compared with native BCR-ABL, and studies indicate that patients with these mutations have a 
worse prognosis. Gatekeeper mutations (eg, the threonine to isoleucine mutation at codon 315 
[T315I] and the phenylalanine to leucine mutation at codon 317 [F317L]) impede contact 
between imatinib and BCR-ABL and, thus, contribute to imatinib resistance and resistance to 
other second-generation TKIs. Different mutants seem to have different degrees of resistance to 
imatinib: in vitro data indicate that while some mutations might be overcome by dose escalation, 
others confer a highly resistant phenotype, thereby suggesting withdrawal of imatinib in favour 
of alternative therapeutic strategies. Indeed, because resistance often coincides with reactivation 
of the kinase activity within the leukaemic clone, either Bcr-Abl itself or Bcr-Abl-triggered 
downstream signaling pathways remain good targets for molecular therapy. Soverini et al. 
reported a high rate of Bcr-Abl mutations in resistant Ph+ ALL patients. Although Bcr-Abl point 
mutations are primarily responsible for the development of secondary, or acquired, resistance in 
Ph+ ALL and CP CML, there are also Bcr-Abl independent mechanisms which are poorly 
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understood 34. BCR-ABL-independent mechanisms include chromosomal abnormalities in 
addition to the Ph chromosome abnormalities (clonal evolution), disruptions in drug uptake and 
efflux, and activation of alternative signaling pathways that cause proliferation or promote cell 
survival. Maintaining effective intracellular drug concentrations also is a major hurdle to 
imatinib efficacy. Imatinib is a substrate of the drug efflux permeability glycoprotein (PgP), and 
increased PgP expression can decrease intracellular concentrations of imatinib to confer drug 
resistance in vitro. Stromal support also has been proposed as a mechanism of resistance to TKIs 
in Ph+ ALL. One study reported that murine p190 BCR-ABL ALL cells with low BCR-ABL 
expression were able to grow in the presence of stroma. Another recently identified mechanism 
of TKI resistance involves the expression of spliced isoforms of IKAROS family zinc (Ikaros) 
(IKZF1), a critical regulator of normal lymphocyte development. Constitutive activation of 
downstream signaling molecules that results in pathway activation, regardless of BCR-ABL 
inhibition, represents another mechanism of imatinib resistance 2,34. 
1.8.2.2 Second-generation tyrosine kinase inhibitors 
Since point mutations are the major mechanism of resistance to first-line imatinib therapy in Ph+ 
leukemia, different drugs active on mutant BCR-ABL or on its signal transduction pathway have 
been developed and tested at clinical level. 
Dasatinib (Sprycel) 
Dasatinib (BMS-354825, Sprycel; Bristol Myers Squibb, NewYork, USA) has reached a peculiar 
and specific role. Dasatinib is a multi-target kinase inhibitor of Bcr-Abl, SFK, ephrin receptor 
kinases, PDGFR and Kit, has 325-fold greater potency than imatinib in cells transduced with 
unmutated BCR-ABL and is active against many of the BCR-ABL mutations, conferring 
imatinib resistance and is effective against the imatinib-resistant active conformation of the 
kinase domain. It is capable of inhibiting the proliferation and kinase activity of wild type and of 
14 out of 15 Bcr-Abl mutant cell lines, except the T315I mutant. Furthermore, the cellular uptake 
of dasatinib is not dependent, as opposed to imatinib, on the organic cation transporter-1 (OCT-
1) activity, although, like imatinib, it is a substrate for efflux proteins. Dasatinib is usually well 
tolerated, but grade 3–4 myelosuppression is common, especially in the advanced phases. Non-
haematological side effects include diarrhea, nausea, headache, peripheral edema and pleural 
effusion. However, resistance to dasatinib is a crucial emerging problem. Not surprisingly, the 
pre-existence or selection of the T315I mutant is the most frequent mechanism of resistance. In 
addition, the emergence of a F317L mutant, which is sensitive to imatinib, has been commonly 
observed in dasatinib-resistant patients. 
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Dasatinib is approved in the United States for patients with Ph+ ALL who have failed to respond 
to imatinib, and clinical trials evaluating its efficacy in patients with newly diagnosed Ph+ ALL 
are ongoing 2,34. 
Nilotinib (Tasignia, AMN107) 
The N-methylpiperazine moiety was originally incorporated into imatinib to improve its 
solubility and oral bioavailability. Substitution of this amide moiety with alternative binding 
groups, while maintaining hydrogen-bond interactions to Glu286 and Asp381, led to the 
discovery of a more potent compound, nilotinib (Tasignia, AMN107, Novartis).  
This highly specific BCR-ABL inhibitor is approximately 30-fold more potent than imatinib and 
is active in vitro against 32 of 33 BCR-ABL mutations, except the T315I mutant. It is a substrate 
for both OCT-1 and efflux proteins. It is superior to imatinib in reducing leukemic burden and 
prolonging the survival of mice transplanted with wild-type BCR-ABL, the M351T and E255V 
mutants. A phase I study of nilotinib in patients with imatinib-resistant CML and Ph+ ALL 
indicated that nilotinib had a relatively favorable safety profile, and responses were noted in a 
subset of adult patients with imatinib-resistant, Ph+ ALL. Specifically, 10% of patients who had 
hematologic relapses achieved a partial hematologic response, and 33% of patients with 
persistent molecular signs of ALL achieved complete molecular remission after nilotinib 
therapy. Myelosuppression was frequent, and common grade 3-4 nonhematologic toxicities 
included indirect hyperbilirubinemia, skin rashes and elevated serum lipase. A subsequent phase 
II study of nilotinib in relapsed or refractory Ph+ ALL reported that 24% patients attained a 
complete hematologic response (CHR). Data from studies in patients with CML indicate that 
BCR-ABL P-loop mutations (eg, tyrosine to phenylalanine or histidine mutation at codon 253 
[Y253F/H] or glutamic acid to methionine or valine mutation at codon 255 [E255K/V]) are 
resistant to nilotinib. Nilotinib is approved only for imatinib-resistant or imatinib-intolerant 
chronic-phase and accelerated-phase CML 2,120. 
Bosutinib (SKI-606;Wyeth) 
Another Src kinase-active TKI is bosutinib (SKI-606; Wyeth). It has a potent anti-proliferative 
activity against imatinib-sensitive and -resistant Bcr-Abl-positive cell lines, including the 
Y253F, E255K and D276G mutants, but not the T315I form. It is able to bind to both inactive 
and intermediate conformations of Bcr-Abl. Unlike dasatinib, bosutinib does not significantly 
inhibit Kit or PDGFR and has a more favourable toxicity profile. The main adverse events are 
commonly gastrointestinal, including diarrhea, whereas myelosuppression usually occurs only in 
the advanced phases 34.  
51 
 
 
 
 
 
 
 
2. AIMS 
 
 
 
 
 
 
 
 
 
52 
 
The 9p21 chromosomal region is a frequent site of genetic loss in several human cancers, 
including solid tumors and hematologic malignancies. This region spans 40 kb of genomic DNA 
and has an unusual and complex genomic organization, encoding three important tumor 
suppressor genes (p16/CDKN2A, p14/ARF and p15/CDKN2B) involved in the regulation of cell 
cycle and/or apoptosis. Disruption of tumor suppressor genes and/or activation of oncogenic 
pathways by point-mutations, amplifications and phosphorylation result in constitutive mitogenic 
signalling and defective responses to anti-mitogenic stimuluses that contribute to unscheduled 
proliferation in tumor cells. Understanding and contrasting the causes of unlimited proliferation 
will allow us to fight the tumor cells. 
In literature several groups studied how the 9p21 chromosome band is inactivated in acute 
lymphoblastic leukemia (ALL), but most of them referred to a small cohort of patients, mainly 
pediatrics, and using low resolution methodologies. 
For example, traditional techniques, that have a limited number of probes, are not able to detect 
small deletions that often occur in this locus. 
To exceed these restraints, in this study, we performed high resolution Affymetrix single 
nucleotide polymorphism (SNP) arrays in 112 Ph+ ALL adult patients (pts) to: 
•   Explore the frequency and size of deletions on 9p21 affecting the CDKN2A/ARF/ 
CDKN2B gene in adult BCR-ABL1-positive ALL patients; 
•   Determine the main mechanism of inactivation of CDKN2A/ARF/ CDKN2B; 
•   Investigate whether the CDKN2A/ARF deletions have any prognostic value; 
We chose to investigate the frequency and role of 9p21 deletions in Ph+ ALL, since it represents 
the most frequent and the most unfavorable subtype of leukemia in adults. It has become clear 
that although BCR-ABL is responsible for transformation of a normal cell in a malignant cell, 
additional and cooperating events are required for leukemia progression. The identification of 
these genetic factors may lead to a more efficacious target therapies. 
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PATIENTS 
All patients gave informed consent to blood collection and biologic analyses, in agreement with 
the Declaration of Helsinki. The study was approved by the Department of Hematology and 
Oncological Sciences “Seràgnoli”. After obtaining informed consent, 112 adult BCR-ABL1-
positive ALL patients, enrolled from 1996 to 2008 in different clinical trials of GIMEMA 
(Gruppo Italiano Malattie EMatologiche dell'Adulto) Acute Leukemia Working Party or in 
Institutional protocols, were analyzed.  
101 (90%) were de novo ALL cases analyzed at the time of diagnosis, while 11 (10%) were 
relapse cases analyzed only at the time of treatment failure. In 19 cases out 101 (19%) both 
diagnosis and relapse samples were collected and thereafter analyzed (Tab. 3.1). 
 
Tab. 3.1. Demographics and Clinical Characteristics of patients with BCR-ABL1 positive ALL analyzed for the 
genomic status of CDKN2A/ARF and CDKN2B. 
 
 
 
Newly diagnosed 
BCR-ABL1 ALL 
(n=101) 
Unpaired Relapse 
BCR-ABL1 ALL 
(n=11) 
Paired Relapsed 
BCR-ABL1 ALL 
(n=19) 
Age (median, range) 51 yrs (18-81) 44 yrs (18-65) 54 yrs (23-74) 
Gender (M/F) 56/45 6/5 10/9 
Blast cell count (%, range) 90 (18-99) 90 (20-96) 90 (25-99) 
BCR-ABL transcript 
        p190 
        p210 
        p190-p210 
 
74 (73%) 
20 (20%) 
7 (7%) 
 
5 (45%) 
5 (45%) 
1 (10%) 
 
11 (58%) 
8 (42%) 
- 
 
 
SINGLE NUCLEOTIDE POLYMORPHISM (SNP) MICROARRAY ANALYSIS 
Genomic DNA was extracted using the DNA Blood Mini Kit (Qiagen, Valencia, CA) from 
mononuclear cells isolated from peripheral blood or bone marrow aspirate samples by Ficoll 
gradient centrifugation. DNA was quantified using the Nanodrop Spectrophotometer and quality 
was assessed using the Nanodrop and by agarose gel electrophoresis. 
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83 samples (63 diagnosis, 20 relapse) were genotyped with GeneChip® Human Mapping 250K 
NspI and 48 samples (38 diagnosis, 10 relapse) with Genome-Wide Human SNP 6.0 array 
microarrays (Affymetrix Inc, Santa Clara, CA) following the manufacturer’s instructions, as 
briefly described in the workflow in the Figure 3.2 121.  
 
 
 
 
Fig. 3.2: Overview of the Genome-Wide Human SNP Assay 6.0.  Briefly, total genomic DNA (500 ng) is 
digested with Nsp I and Sty I restriction enzymes and ligated to adaptors that recognize the cohesive 4 bp overhangs. 
All fragments resulting from restriction enzyme digestion, regardless of size, are substrates for adaptor ligation. A 
generic primer that recognizes the adaptor sequence is used to amplify adaptor-ligated DNA fragments. PCR 
conditions have been optimized to preferentially amplify fragments in the 200 to 1,100 bp size range. PCR 
amplification products for each restriction enzyme digest are combined and purified using polystyrene beads. The 
amplified DNA is then fragmented, labeled and hybridized to the array. 
http://www.affymetrix.com/_media/images/assayimage.gif 
 
The new Affymetrix Genome-Wide Human SNP Array 6.0 features 1.8 million genetic markers, 
including more than 906,600 single nucleotide polymorphisms (SNPs) and more than 946,000 
probes for the detection of copy number variation. The high number of SNPs and non 
polymorphic probes (NNPs) enable to have a good coverage, spaced along the genome, with a 
median distance between markers of only 700 bp (Tab. 3.2).  
 
 Tab. 3.2 Genome-Wide Human SNP Assay 6.0 features.
 
 
 
Copy number aberrations were scored using the segmentation
Partek Genomics Suite TM software package (http://www.partek.com/) as well as by visual 
inspection and by a comparison with a set of 270 H
samples obtained from 25 acute lymphoblastic leukaemia cases in remission in order to reduce 
the noise of raw copy number data. Affymetrix CEL files were also imported in and analyzed by 
dChip (www.dchip.org)122. Copy numbers per SNP marker were generated according to 
Mullighan et al.123 and imported into UCSC Genome Browser website (http://genome.ucsc.edu/) 
for visualization. In the Figure 
Genome-Wide Human SNP 6.0 array is shown. Loss of heterozygosity (LOH) was analyzed 
using Genotyping Console v3.1 (Affymetrix Inc.).
 
 
 
 approach available within the 
apMap normal individuals and a set of 
3.3 the probe density in CDKN2A/ANRIL/CDKN2B
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 locus on 
  
Fig. 3.3 UCSC genome browser screenshot of a region on chromosome 9p21 (20
containing the CDKN2A and CDKN2B
locus (ANRIL or CDKN2BAS). Markers on Affymetrix SNP6.0 are shown as black lines on the  bottom of the 
figure. ANRIL overlaps the two exo
CDKN2A-ARF gene cluster. Exon 1 of 
1β of CDKN2A. Original image at 
bin/hgTracks?insideX=118&revCmplDisp=0&hgsid=187245851&hgt_doJsCommand=&hgt.out1=1.5x&position=c
hr9%3A21869592-
22072649&hgtgroup_map_close=0&hgtgroup_phenDis_close=1&hgtgroup_genes_close=0&hgtgroup_rna_close=0
&hgtgroup_expression_close=0&hgtgroup_regulation_close=0
al_close=0&hgtgroup_denisova_close=0&hgtgroup_varRep_close=0&hgtgroup_encodeGenes_close=0&hgtgroup_
encodeTxLevels_close=0&hgtgroup_encodeChip_close=0&hgtgroup_encodeChrom_close=0&hgtgroup_encodeCo
mpAndVar_close=1.  
  
 genes and a newly annotated  antisense noncoding RNA in the 
ns of CDKN2B and is transcribed in the orientation opposite to the 
ANRIL is present about 300 bp upstream of the transcription start site of exon 
http://genome.ucsc.edu/cgi
&hgtgroup_compGeno_close=0&hgtgroup_neandert
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,283,199-20,587,785) 
INK4 
CDKN2B-
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FLUORESCENCE IN SITU HYBRIDIZATION (FISH) AND PROBES 
FISH analysis was performed as previously described124. Briefly, chromosome preparations from 
bone marrow cells were hybridized in situ with 1 µg of probe labeled by nick translation. 
Hybridization was performed at 37°C in 2X SSC, 50% (vol/vol) formamide, 10% (wt/vol) 
dextran sulfate, 5 µg COT1 DNA (Bethesda Research Laboratories, Gaithersburg, MD, USA), 
and 3 µg sonicated salmon sperm DNA in a volume of 10 µL. Post-hybridization washing was 
performed at 60°C in 0.1X SSC (three times). In cohybridization experiments, the probes were 
directly labeled with Fluorescein and Cy3. Chromosomes were identified by DAPI staining. 
Digital images were obtained using a Leica DMRXA epifluorescence microscope equipped with 
a cooled CCD camera (Princeton Instruments, Boston, MA). Cy3 (red; New England Nuclear, 
Boston, MA, USA), fluorescein (green; Fermentas Life Sciences, Milan, IT), and DAPI (blue) 
fluorescence signals, which were detected using specific filters, were recorded separately as 
gray-scale images. Pseudocoloring and merging of images were performed with Adobe 
Photoshop software.  
Bacterial artificial chromosome (BAC) [RP11-70L8 (Accession Number 
AL359922)(chr9:21,732,609-21,901,258), RP11-149I2 (Accession Number 
AL449423)(chr9:21,899,259-22,000,413), and RP11-145E5 (Accession Number AL354709) 
(chr9:21,998,414-22,155,946)] and fosmid [G248P82557D2 (Accession Number WIBR2-
1053H3) (chr9:21,975,653-22,011,179), and G248P82010F5 (Accession Number WIBR2-
1034K10) (chr9:21,926,491-21,967,852)] probes, specific for the MTAP-CDKN2A-CDKN2B 
locus, as well as a BAC for BCR gene [RP11-164N13 (chr22:21,897,904-22,091,572)], were 
properly selected accordingly to the March 2006 release of the University Santa Cruz (UCSC) 
Human Genome Browser (http://genome.ucsc.edu/cgi-
bin/hgGateway?hgsid=169374627&clade=mammal&org=Human&db=hg18). 
 
CDKN2A GENE EXPRESSION LEVELS  
Total cellular RNA was extracted using the RNeasy total RNA isolation kit (Qiagen, Valencia, 
CA) and one microgram was reverse transcribed using the High Capacity cDNA Archive Kit 
(Applied Biosystems, Foster City, CA). Quantitative Polymerase chain reaction (PCR) analysis 
was performed using Hs00924091_m1 assay (Applied Biosystems) and the Fluidigm Dynamic 
Array 48 x 48 system, a real-time quantitative PCR assay which enables to automatically 
assemble 48 samples and 48 assays to create individual TaqMan reactions of a final volume of 
6.75 nanolitres each (Fluidigm, San Francisco, CA, http://www.fluidigm.com/). The Fluidigim 
 BioMark system (Fig. 3.4-A) provides orders of magnitude higher throughput for real
quantitative PCR compared to con
chips that contain fluidic networks that automatically combine sets of samples with sets of 
assays.  
 
Fig 3.4 (A) The BioMark Real-Time PCR system
position of the sample inlets and the detector inlets in which the gene expression assay reagents are added. The 
check valves allow pressure to be applied and released. The accumulators provide reservoirs to hold the pressure and 
keep the valves closed during the reaction. The integrated Fluidic Circuit (IFC) is in the center of the chip. This is a 
network of fluid lines, NanoFlex™ valves and reaction chambers. The insert shows a blow
IFC with one of the 2304 individual reac
interface valve (IV) There are two containment valves and one interface valve associated with each reaction 
chamber.  
 
The BioMark cassette works using thousands of NanoFlex(TM) valves to fi
individual reactions from a matrix of samples and primers. 
Array (Fig 3.4-B) systematically combine 48 samples and 48 assays in 
reactions, of final reaction volume of 
placed on the BioMark Real Time PCR system for thermal cycling and real
detection. To examine, annotate, and archive the data (Fig. 3.5), the BioMark Real Time 
Analysis Software was used. 
ventional platforms due to its dynamic arrays
 
. (B) Photograph of a 48x48 dynamic array chip
tion chambers (RC) and the associated containment valves (CV) and 
Particularly, t
6.75 nanolitres each. After setup, the dynamic array is 
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 showing the 
-up of a portion of the 
ll thousands of 
he 48x48 Dynamic 
2.304 real-time qPCR 
-time fluorescence 
 Fig 3.5 The BioMark Real Time Software generated image
obtained after thermal cycling of the chip. Each of the squares represents 1 reaction chamber from the chip. The 
color indicates the CT value according to the lege
on a cell, corresponding to a single reaction, its data and graph curves are activated (right).
 
RNA integrity was confirmed
which is expressed ubiquitously in human hematopoietic cells. Results were expressed as 2exp(
∆∆Ct). GraphPad Prism 5 software (GraphPad, Avenida de la Playa La Jolla, CA USA) was 
used to determine the statistical significance of 
patients and to plot the data for 
 
CDKN2A/ARF AND CDKN2
Genomic re-sequencing of all coding exons of 
search of mutations using primers listed in Table 1S. Two diff
used in a final reaction of 25 
Biosystems) each PCR reaction was performed using: 30
primers; 10X PCR Gold Buffer; 2.5 mM MgCl2; 200 
Gold DNA Polymerase; water to
(Roche, Mannheim, Germany), each PCR reaction was performed using: 30
DNA; 25 pmoli of primers; 10X PCR Buffer; 2.5 mM MgCl2 Solution; 200 
FastStart Taq DNA Polymerase;
 
 
 (left), heat map, of a 48x48 dynamic array chip 
nd shown on the right. Black chambers indicate a C
 by PCR amplification of the GAPDH mRNA (Hs99999905_m1), 
CDKN2A expression levels in differen
the figure 4.4. 
B POINT MUTATION SCREENING
CDKN2A/ARF and CDKN2
erent Taq DNA polymerases were 
µl. For AmpliTaq Gold DNA Polymerase LD protocol (Applied 
-50 ng of genomic DNA; 25 pmoli of 
µM dNTPs; DMSO 2.5%; 1U AmpliTaq 
 final volume. For Fast Start Taq DNA Polymerase protocol 
 water to final volume (Tab. 3.3).  
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Gene Exon Sequence (5’→3’) Tm (C°) 
Amplicon 
size (bp) 
DNA 
polymerase 
PCR 
protocol 
(*) 
CDKN2A 1α AGTCCTCCTTCCTTGCCAAC 60.63 
508 AmpliTaq Gold  
95° x 30" 
62° x 30" 
72° x 50" 
CDKN2A 1α CGCTGCAGACCCTCTACC 59.53 40 cycles 
CDKN2A 
sequencing 1α GCTGCAGACCCTCTACCC 58.32 -  
 
ARF 1β TGCTCACCTCTGGTGCCAAAG 58.60 
218 FastStart 
95° x 30" 
60° x 30" 
72° x 30" 
ARF 1β CTCAGTAGCATCAGCACGAGG 58.60 35 cycles 
CDKN2A/ARF 2 CCTGGCTCTGACCATTCTGT 60.26 
421 AmpliTaq Gold  
95° x 30" 
63° x 30" 
72° x 1' 
CDKN2A/ARF 2 GGCTGAACTTTCTGTGCTGG 60.98 40 cycles 
CDKN2A/ARF 3 TACATGCACGTGAAGCCATT 60.14 
685 FastStart 
95° x 30" 
62° x 30" 
72° x 1' 
CDKN2A/ARF 3 TCTTCCATGCGATGAAATTG 59.62 40 cycles 
CDKN2B 1 TGAAAACGGAATTCTTTGCC 60.05 
632 FastStart 
95° x 30" 
62° x 30" 
72° x 1' 
CDKN2B 1 ACATCGGCGATCTAGGTTCC 61.38 35 cycles 
CDKN2B 2 GGCTCTGACCACTCTGCTCT 59.74 
463 FastStart 
95° x 30" 
62° x 30" 
72° x 1' 
CDKN2B 2 ATGGAAGGTTATTCCCGGTC 60.02 35 cycles 
 
 
Tab. 3.3 Primers used for amplification of CDKN2A/ARF and CDKN2B genes, and relative PCR protocol. (*) 
Protocols with AmpliTaq Gold polymerase involve an initial denaturation of 7’ at 95°C, whereas protocols with 
FastStart polymerase involve an initial denaturation of 5’ at 95°C. Both polymerase have an extension of 7’ at 72°C. 
 
PCR products were purified using QIAquick PCR purification kit (Qiagen) and then directly 
sequenced using an ABI PRISM 3730 automated DNA sequencer (Applied Biosystems, Foster 
City, CA) and a Big Dye Terminator DNA sequencing kit (Applied Biosystems, Foster City, 
CA). In some cases the PCR products were sub-cloned into the PCR®2.1-TOPO vector using the 
TOPO TA Cloning Kit (Invitrogen, San Diego, CA). The cloned PCR products were purified and 
sequenced as described above. All sequence variations were detected by comparison using the 
BLAST software tool (www.ncbi.nlm.nih.gov/BLAST/) to reference genome sequence data 
(GenBank accession number NM_000077.4, NM_058195.3 e NM_004936, for CDKN2A, ARF, 
 CDKN2B, respectively) obtained from t
bin/hgGateway?db=hg18; March 2006 release). 
 
MUTATION SCREENING IN 
Almost 2ml of saliva samples were collected from 5 patients and mixed with 2 ml DNA
preserving solution contained in the 
Format, DNA Genotek Inc., Kanata, Ontario, Canada 
instructions (Fig. 3.7) and stored at room temperature or 
 
Fig. 3.6 Oragene® DNA Self-Collection Kit (
provides an all-in-one system for the collection, stabilization, transportation and purification of DNA from saliva. 
The kit contains a tube with 2 ml Oragene DNA solution in the 
removing the funnel; a multilanguage donor user instructions
 
Fig. 3.7 Oragene® DNA Self-Collection Kit User Instructions. (a) 
reaches the fill line; (b) Close lid by pushing down hard on the funnel lid. The liquid in it will be released into the 
tube to mix with the saliva; (c) Unscrew the tube from the funnel; 
he UCSC browser (http://genome.ucsc.edu/cgi
 
SALIVA SAMPLES 
Oragene® DNA Self-Collection Kit Oragene (
- Fig. 3.6), according to the manufacturer's 
-20°C till DNA extraction
 
 
OG-500 DNA Tube Format). The OG
funnel lid; a small cap to close the tube after 
 sheet. 
Spit until the amount of saliva (not bubbles) 
(d) Close tube tightly with small cap and mix.
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-
-
OG-500 Tube 
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Briefly, the vials were incubated for 1 hours and 30 minutes in a 50°C water incubator and then 
could be stored at room temperature or frozen (-15°C to -20°C), or it could be immediately 
processed. In this case, 500 µl of the mixed Oragene DNA/saliva sample were transferred to a 
1.5 ml microcentrifuge tube, then 20 µl (1/25th volume) of Oragene DNA Purifier (OG-L2P, 
supplied) were added to it and were mixed by vortexing for a few seconds, before incubating on 
ice for 10 minutes. The samples were then centrifuged for 8 min at 13,000 rpm (15,000 × g) at 
room temperature and supernatants were transferred to new microcentrifuge tubes and discard 
the pellet containing impurities. 500 µl of room-temperature 95-100% ethanol were added to 500 
µl of supernatant (an equal volume) and mixed gently by inversion 10 times. The samples were 
then centrifuged for 2 min at 13,000 rpm at room temperature, supernatants were discarded. 250 
µl of 70% ethanol were added for 1 minute and carefully removed. DNA’s pellets were dissolved 
in 30-50 µL AE buffer (Qiagen, Valencia, CA). The DNA samples were stored at −20°C until 
PCR analysis. DNA yield and purity were determined by measuring the absorbance at 260 nm 
(A260) and the ratio of absorbance at 260 nm and 280 nm (A260/A280) at the Nanodrop 
Spectrophotometer. The quality of DNA was confirmed by running 100 ng hydrated DNA on a 
1% agarose gel. 
 
STATISTICAL ANALYSIS 
Differences in the distributions of prognostic factors in subgroups were analyzed by χ2 or 
Fisher’s exact test, and by Kruskal-Wallis test. Median follow-up time was estimated by 
reversing the codes for the censoring indicator in a Kaplan-Meier analysis 125. Overall Survival 
was defined as the time from diagnosis to date of death or date of the last follow-up. DFS and 
Cumulative Incidence of Relapse were calculated from the time of achieving CR to date of first 
relapse, death or date of last follow-up. The probabilities of OS and DFS were estimated using 
the Kaplan-Meier method 125 and the probability of Cumulative Incidence 126 of relapse was 
estimated using the appropriate non-parametric method, considering death in CR as competing 
risk. The log-rank test was used to compare treatment effect and risk factor categories for the 
Kaplan-Meier curves and the Gray test for the Incidence curves. Confidence intervals where 
estimated (95% CIs) using the Simon and Lee method 127.  
Cox proportional hazard regression model 128 was performed to examine and check for treatment 
results and the risk factors affecting Disease Free Survival. 
All tests were 2-sided, accepting p ≤0.05 as indicating a statistically significant difference. All 
analyses where performed using the SAS software (SAS Institute, Cary, NC).  
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4. RESULTS 
 
 
 
 
 
 
 
 
  
 SNP microarray analysis detects frequent and recurrent deletions in CDK
CDKN2B genes at diagnosis and during leukemia progression
In order to detect the frequency and size of deletions occurring at 9p21 locus in 
positive ALL, data generated by high
diagnosis (n=82), relapse (n=11) or at both time points (n=19). At diagnosis, 
ANRIL genomic alterations were identified in 29 (29%) patients. 
about 300 bp upstream of the transcription start site of exon 1
its 5‘ end the two exons of CDKN2B. 
two exons of CDKN2B. Deletions were monoalleli
median of 1,012 kb in size (range, 2.8
CDKN2A/ANRIL/CDKN2B losses, the minimal overlapping region of the lost area spanned only 
the two genes, but more often (12/29, 57%) the l
sometimes (3/29, 10%) over the entire short chromosome arm eliminating
genes (Fig. 4.1-A). In contrast, cases with bi
majority of deletions (6/8, 75%) 
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-resolution SNP arrays were analyzed in adult patients a
ANRIL ha
β of CDKN2A
In 25 patients (25%) genomic deletions also included the 
c in the majority of cases (72%) with a 
-31,319 kb). In 9/29 (43%) patients with 
oss was considerable larger and extended 
-allelic inactivation were 8/29 (28%) with the 
limited to CDKN2A/ANRIL/CDKN2B genes (Fig.
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 Fig. 4.1. Schematic representation of heterozygous (A) and homozygous (B) deletions
genomic locus in adult BCR-ABL1 positive ALL patients. Gray bars indicate large deletions ex
CDKN2A/ANRIL/ARF genes; black bars indicate small deletions spanning only the 
schematic position and size of MTAP, CDKN2A, ANRIL
 
 
Next, in order to investigate whe
involved in disease progression, the genomic status of the 9p21 locus was assessed at the time of 
relapse in 30 patients (11 unpaired and 19 paired relapsed cases). In an unpaired analysis, an 
almost significant increase in the detection rate of 
(29%) (p = 0.06) was found by a non parametric 
we found that both at diagnosis and relapse deletions were heterozygous in 
(72% vs 28%) (Tab. 4.1).  
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CDKN2A/ANRIL/ARF
 and CDKN2B genes are also reported as white bars
ther the deletions of CDKN2A/ANRIL/CDKN2B
CDKN2A loss (47%) compared to diagnosis 
t-test. When we analyzed the type of deletion, 
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Diagnosis 
(n = 101) % 
Relapse 
(n = 30) % 
CDKN2A 
Deletion 
Heterozygous 21 20.8 10 33.3 
Homozygous 8 7.9 4 13.3 
Total 29 28.7 14 46.6 
ANRIL 
Deletion 
Heterozygous 23 22.8 10 33.3 
Homozygous 6 5.9 3 10.0 
Total 29 28.7 13 43.3 
CDKN2B 
Deletion 
Heterozygous 19 18.8 9 30.0 
Homozygous 6 5.9 3 10.0 
Total 25 24.8 12 40 
 
 
Tab. 4.1. Deletion rates of CDKN2A/ANRIL/CDKN2B at diagnosis and relapse. 101 patients were analyzed at 
diagnosis, whereas 11 patients (including paired and unpaired cases) were analyzed at the time of relapse. The table 
shows the numbers and percentages of BCR-ABL1-positive ALL patients with heterozygous and homozygous 
deletions at diagnosis and at relapse. 
 
 
FISH analysis confirmed large deletions 
FISH experiments with BACs and fosmids encompassing the whole MTAP-CDKN2A-CDKN2B 
locus (Fig. 4.2-A) were performed in six BCR-ABL1-positive ALL patients, in order to confirm 
the deletion disclosed by SNP array analysis. 
The deletion was detected (at FISH resolution) in two cases, as all the used MTAP-CDKN2A-
CDKN2B probes were shown to be heterozygously deleted on chromosome der(9) in Ph+ 
metaphases [identified by the splitting signal of RP11-164N13, observed respectively on der(9) 
and Ph chromosomes] (Fig. 4. 2-B,C and data not shown).  
The same probes failed to identify the deletion in the other four patients under study (data not 
shown), due to the limited size of the deletion spanning only the two genes and behind the limits 
of FISH resolution, as verified by SNP array. 
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Fig. 4.2 (A) Map of the clones used in FISH experiments to detect MTAP-CDKN2A-CDKN2B deletions, showing 
BACs, fosmids, and genes respectively with red, blue, and green bars. (B) and (C) FISH results obtained in patients 
#1 and #2, respectively, showing a MTAP-CDKN2A-CDKN2B heterozygous deletion. (B) Only one fluorescent 
signal of both BACs (on the left) and fosmids (on the right) observed on normal chromosome 9 in Ph positive 
metaphases (as shown by the three signals of RP11-164N13); (C) Colocalization of all the MTAP-CDKN2A-
CDKN2B BAC probes only on normal chromosome 9. No signal on der(9).  
 
 
Deletions lead to a down-expression of CDKN2A levels 
In order to investigate the functional consequences of genomic deletions affecting the 9p21 
locus, the CDKN2A transcript levels were assessed by quantitative RT-PCR in three different 
groups of BCR-ABL1 positive ALL patients: 1) CDKN2A wild-type cases (n = 18); 2) CDKN2A 
heterozygous deleted cases (n = 5); 3) CDKN2A homozygous deleted cases (n = 7). The 
Hs00924091_m1 assay (Applied Biosystems) amplifying the 1-2 exon boundary of CDKN2A 
(reference sequence NM_058195.3) was used. Results showed a significant decrease of the 
expression of CDKN2A in heterozygous deleted cases (p = 0.04) and in homozygous deleted 
cases (p = 0.01) compared to cases without deletion. The median CDKN2A expression level 
expressed as 2exp(-∆∆ct) in diploid cases was 2.86 (range, 0.81-14.41) versus 0.19 (range, 0.10-
0.53) and 0.004 (range, 0.0003-0.0653) of cases with mono-allelic and bi-allelic losses, 
respectively (Fig. 4.3).  
  
Fig. 4.3 Expression levels of CDKN2A
heterozygous CDKN2A deletion; 3) homozygous 
parametric t-test was used to compare group 1 
group 3 (p = 0.004).  
 
A significant difference in the expression of 
heterozygous and homozygous deletions (
lead to CDKN2A haploinsufficiency. 
 
CDKN2A/ARF and CDKN2B mutation screening
9p21 locus can be inactivated in many tumors due to several mechanisms in addition to 
deletions, such as hypermethylation of promoter regions and inactivating mutations. Since 
hypermethylation is a rare event in acute lymphoblastic leukemia
investigate the frequency of point mutations occurring in 
address this issue, a mutation screening o
and 3) and CDKN2B (exons 1 and 2) genes was successfully performed on patients who were 
known to have retained by SNP array at least one 
type (Tab. 4.2).  
  
 in BCR-ABL1 positive ALL patients with: 1) wild
CDKN2A deletion. Results are expressed as 2exp(
vs group 2 (p = 0.04), group 1 vs group 3 (p = 0.01) and group 2 
CDKN2A was also observed among cases with 
p = 0.004). Overall, these results suggest that deletions 
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f all coding exons of CDKN2A/ARF 
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CDKN2A Ex 1α 
    N  % 
Diagnosis (n = 30) 
  
WT 5 16.7 
5’ UTR 21965017 A 11 36.6 
5’ UTR 21965017 G/A 14 46.7 
All mutated pts   25 83.3 
Relapse (n = 10) 
 
  
  
WT 1 10.0 
5’ UTR 21965017 A 2 20.0 
5’ UTR 21965017 G/A 6 60.0 
5’ UTR 21964851 C/T 1 10.0 
All mutated pts   9 90.0 
ARF Ex 1β 
 
  N  % 
Diagnosis (n = 35) WT 35 100.0 
Relapse (n = 12) WT 12 100.0 
CDKN2A/ARF 
 Ex 2 
 
  N  % 
 Diagnosis (n = 32) 
  
  
  
WT 24 75.0 
rs3731249 A A148T 1 3.0 
rs3731249 G/A A148T 5 16.0 
D146NCDKN2A/ 3’UTRARF 
21960922  1 3.0 
R128CDKN2A/3’ UTRARF 
21960974 1 3.0 
All mutated pts   2 6.3 
Relapse (n = 12)  WT 12 100.0 
CDKN2A/ARF 
 Ex 3 
 
  N  % 
 Diagnosis  (n = 36) 
  
  
WT 2 6.0 
3’ UTR rs11515 C 22 67.0 
3’ UTR rs11515 C/G 11 34.0 
3’ UTR rs11515 C 
3’ UTR rs3088440 C/T 
1 3.0 
Relapse (n = 11) WT 0 0 
  
  
  
3’ UTR rs11515 C 8 80.0 
3’ UTR rs11515 C/G 2 20.0 
3’ UTR rs3088440 C/T 1 10.0 
CDKN2B Ex 1 
 
  N  % 
Diagnosis  (n = 42) WT 42 100.0 
Relapse (n = 14) WT 14 100.0 
CDKN2B Ex 2 
 
  N  % 
Diagnosis  (n = 42) WT 41 97,6 
P83 1 2,4 
Relapse (n = 15) WT 15 100,0 
 
 
Tab. 4.2. Amplification and sequencing of CDKN2A/B in BCR-ABL1-positive ALL patients (pts) at diagnosis 
and relapse; results including wild-type (WT) or mutated sequenze are reported for each exon (Ex). 
71 
 
Samples tested were from diagnosis (n = 30 for exon 1α of CDKN2A; n = 35 for exon 1β of 
CDKN2A; n = 32 for exon 2 of CDKN2A; n = 36 for exon 3 of CDKN2A; n = 42 for exon 1 and 
2 of CDKN2B) and relapse (n = 10 for exon 1α of CDKN2A; n = 12 for exon 1β of CDKN2A and 
exon 2 of CDKN2A; n = 11 for exon 3 of CDKN2A; n = 14 for exon 1 of CDKN2B; n = 14 for 
exon 2 of CDKN2B). Amplification and sequencing results showed that in the analyzed subset of 
patients non-synonymous point mutations in coding exons are rare with only one patient 
harboring a somatic non-synonymous mutation. This was detected in a diagnosed sample and 
involved a base substitution of G >A in exon 2 of CDKN2A at codon 146, that resulted in a 
substitution of aspartic acid in asparagine (D146N). A base substitution of G >A in the same 
exon at codon 128 was identified in another case but it resulted in a synonymous substitution of 
arginine (R128). Additional mutations have been identified in the 5’ untraslated region (UTR) of 
CDKN2A exon 1α at position 21965017, 191 bp before the start codon, 
(http://genome.ucsc.edu/cgi-bin/hgGateway?db=hg18; March 2006 release) with a heterozygous 
substitution of G > A in 46.7% of diagnosis patients and in 60.0% of relapse cases. This 
substitution was homozygous in 36.6 % of diagnosis cases and in 20.0% of relapse cases. In the 
same region but at position 21964851, 25 bp before the start codon, a heterozygous substitution 
of C >T was found in only one patient at relapse (10%). Frequent nucleotide variations were 
identified in exons 2 and 3 of CDKN2A but they resulted in known SNP after comparison with 
the database dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/). These variations include the 
following known single nucleotide polymorphisms: rs3731249 G/A, rs11515 C/G and rs3088440 
C/T. The rs3731249 G/A is located in the exon 2 of CDKN2A and it is responsible for a non-
synonymous substitution of alanine with threonine at codon 148. The rs11515 C/G and 
rs3088440 C/T polimorphisms are located in the 3’ UTR. The first and second exons of 
CDKN2B resulted wild-type, except for the silent mutation at codon 83 (P83) identified in one 
case at diagnosis (Tab. 4.2 and Fig. 4.4). 
 
  
 
Fig. 4.4 Electropherograms of mutations identified
CDKN2A/ARF/CDKN2B genes. For each mutation an electropherogram showing five nucleotides with the starred 
mutated base in the middle is showed in the first column. The wild
Overall we identified the following mutations: two nucleotide
CDKN2A; one substitution at genomic position 21960922 corresponding to a non
the exon 2 of CDKN2A and a variation in the 3’UTR of 
corresponding to a synonymous mutation of 
mutation in the exon 2 of CDKN2B. 
  
 by PCR and subsequent sequencing of 
-type alleles are reported in the second column. 
 substitutions in the 5’ untraslated region (UTR) of 
-synonymous mutation (D146N) in 
ARF gene; one substitution at genomic posi
CDKN2A (R128) and a variation in the 3’UTR of ARF gene; a silent 
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tion 21960974 
 Comparison between leukemia and germline DNA samples
In order to assess whether the nucleotide sub
acquired at the time of leukemia (somatic mutations), we compared the leukemia DNA samples 
with those obtained from collection of saliva after written informed consent. For this analysis 5 
cases were available. PCR was performed on the promoter region and exon 1
assess the mutational status of the substitution at position 21965017 since the remaining exons 
resulted wild-type or containing single nucleotide polymorphisms. Results showed that the 
mutation was inherited for the cases #1, #2 and #3; it was acquired by the leukemia blast cells 
from the case #4 and interestingly the case #2 showed a weird pattern with the mutation in the 
germline/saliva sample and with the wild
 
 
Fig. 4.5 Comparison between leukemia and saliva DNA samples
promoter region and exon 1α of CDKN2A
since the remaining exons resulted wild
 
stitutions identified in CDKN2A/B
-type allele in the leukemia sample (
. PCR was performed in 5 cases on on the 
  to assess the mutational status of the substitution at position 21965017 
-type or containing single nucleotide polymorphisms. 
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 genes where 
α of CDKN2A to 
Fig. 4.5). 
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CDKN2A/B deletions and correlation with clinical outcome 
Finally, after having demonstrated that deletions are the main mechanism of inactivation, we 
investigated their implications in leukemia. Therefore, in order to determine whether deletions in 
CDKN2A/B genes could impair response to treatment in BCR-ABL1 positive ALL patients, 
clinical data were collected from 81 patients. The median follow-up was 25.2 months (range 2.1-
148.1). Patient’s characteristics are reported in Table 4.3.  
 
Variable 
BCR-ABL1-positive 
ALL patients (n=81) % 
Age (median, range) 53.71 yrs (18-76)  
Gender (M/F) 48/33  
White blood cell count (x10^9/L) 21.95 (0.40-302.00)  
CDKN2A/B Loss  
CDKN2A/B Normal  
29 
52  
35.80 
64.20 
Protocol* 
   LAL2000 
   LAL1205 
   LAL0201-B 
   Institutional 
 
13 
47 
12 
9 
 
16.05 
58.02 
14.81 
11.11 
Follow-up, months 
Median (range) 
 
25.2 mesi (2.1-148.1) 
 
 
 
Tab. 4.3 Demographics and Clinical Characteristics of patients with BCR-ABL1 positive ALL analyzed for 
the genomic status of CDKN2A/ARF and CDKN2B and for correlation with clinical outcome. *Protocol 
LAL0201-B enrolled elderly (>60 years) Ph+ ALL patients who received imatinib, 800 mg daily, associated to 
steroids as frontline treatment; LAL2000 enrolled adult (>18 years) ALL patients, including Ph+ cases, who 
received induction and consolidation chemotherapy followed by maintenance therapy with imatinib; LAL1205 
enrolled adult Ph+ ALL patients who received Dasatinib 70mg/bid for 84 consecutive days, as induction therapy, 
initially associated to steroids without further chemotherapy as frontline treatment. 
 
 
Briefly, the median age at diagnosis was 53.71 years (range, 18-76), the median white blood cell 
count was 21.95 (x10^9/L) (range, 0.40-302.00) and CDKN2A/B was lost in 29 (35.80%) cases. 
72 patients (89%) were enrolled in the GIMEMA clinical trials (12 patients in GIMEMA 
 LAL0201-B protocol, 13 in LAL2000 and 47 in the LAL1205 protocols), while 9 patients (11%) 
were enrolled into institutional protocols. Details of the treatment schemes have been previously 
reported129. A univariate analysis of the 
outcome was performed. A shorter overall survival (OS) and disease
found in patients with CDKN2A/B
months, respectively, p = 0.0206; DFS: 10.1 vs 56.1 months, respectively,
Moreover, a higher cumulative incidence of relapse (CIR) for patients with 
versus patients wild-type (73.3 vs 38.1; 
 
 
 
Fig. 4.6 Overall Survival (A), disease
BCR-ABL1-ALL patients enrolled in different clinical trials of GIM
  
CDKN2A/B genomic status and its association with 
-free survival (DFS) were 
 deletion compared with wild-type patients (OS: 27.7 v 38.2 
p = 0.0014) was also recognized (Fig. 4.6
-free survival (B) and cumulative incidence of relapse (C)
EMA according to CDKN2A/B 
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 p = 0.0010). 
CDKN2A/B deletion 
 and Tab. 4.4).  
 
 of de novo 
deletions.  
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CDKN2A/B loss 
% (C.I. 95%) 
CDKN2A/B  wild-
type 
% (C.I. 95%) 
Pr > Chi-
Square 
Cumulative 
Incidence of 
Relapse 
(CIR) 
Patients 27 51 
0.0014 at 24 mo 73.3% (71.6-75.1) 38.1% (37-39.2) 
Median time 10.1 mo 56.1 
Disease free 
survival (DFS) 
Patients 27 51 
0.0010 at 24 mo 22.2% (18.8-26.3) 57.6% (49.8-66.7) 
Median time 10.1 mo 56.1 mo 
Overall 
survival (OS) 
Patients 29 52 
0.0206 at 24 mo 57.2% (46.5-70.4) 77.8% (68.7-88.1) 
Median time 27.7 mo 38.2 mo 
 
Tab. 4.4. Clinical outcome related to CDKN2A/B loss in univariate analysis. Abbreviations: mo (months), wt 
(wild-type); CIR: Cumulative Incidence of Relapse; DFS: Disease- Free Survival; OS: Overall Survival 
 
Noteworthy, the multivariate analysis confirmed the negative prognostic impact of CDKN2A/B 
deletion on DFS (p = 0051;Tab. 4.5 ). 
 
 Hazard ratio 95% CI p-value 
CDKN2A/B genomic status    
CDKN2A/B loss vs. CDKN2A/B wild-type 2.441 1.306-4.506 0.0051 
Age 0.985 0.959-1.011 0.2405 
Wbc at diagnosis 1.005 0.999-1.005 0.0734 
Protocol treatment    
LAL1205 vs. LAL0201B 1.009 0.423-2.409 0.9839 
LAL2000 vs. LAL0201B 1.641 0.536-5.024 0.3856 
other protocols vs. LAL0201B 0.766 0.253-2.316 0.6366 
 
Tab. 4.5. CDKN2A/B loss and other clinical relevant factors for predicting Disease Free Survival 
(multivariate analysis). 
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5. DISCUSSION 
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CDKN2A and ARF share common second and third exons, but different exon 1 (exon 1α for 
CDKN2A and exon 1β for ARF) and therefore they are translated in alternate reading frames, 
exhibiting no protein sequence similarity. Functionally, CDKN2A is a cyclin-dependent kinase 
inhibitor, whereas ARF (p19 Arf in mice) regulates p53 tumour suppressor function through its 
interaction with Mdm2 130. CDKN2B lies adjacent to CDKN2A/ARF and it encodes p15INK4B, a 
cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents 
the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator 
that controls cell cycle G1 progression.  
In literature several groups studied how the 9p21 chromosome band is inactivated in ALL, but 
most of them referred to a small cohort of patients, mainly pediatric and using low resolution 
methodologies. For example, traditional techniques, that have a limited number of probes, are 
not able to detect small deletions that often occurs in this locus and may underestimate the real 
occurrence. 
Therefore, in this study, to exceed these restraints we performed high resolution Affymetrix SNP 
arrays in 112 Ph+ ALL adult patients with the aims to explore the frequency and size of deletions 
on 9p21 affecting the CDKN2A/ARF/CDKN2B genes in adult BCR-ABL1-positive ALL patients; 
to determine the main mechanism of inactivation and to correlate deletions with clinical 
outcome. 
In ALL patient samples, the size and position of 9p21.3 deletions seem to vary substantially, but 
in most cases CDKN2A is co-deleted with CDKN2B and 77,79,1 the frequency of genomic 
deletions is 21% in B-cell precursor ALL and 50% in T-ALL patients.  
In this study, by high-resolution single nucleotide polymorphisms arrays we identified at 
diagnosis, CDKN2A/ARF and ANRIL genomic alterations in 29% of BCR-ABL1 positive ALL 
patients. In 25% of cases genomic deletions also included the two exons of CDKN2B. Deletions 
were predominantly monoallelic and the minimal overlapping region of the lost area in more 
than half of leukemia cases (57%) was considerable large and extended sometimes (10%) over 
the entire short chromosome arm eliminating a large number of genes.  
To investigate whether deletion of CDKN2A/ARF could be involved in disease progression, the 
genomic status of 9p21 locus was assessed at the time of relapse and an almost significant 
increase in the detection rate of CDKN2A/ARF loss (47%) compared to diagnosis (p = 0.06) was 
found, suggesting that loss of this genomic region is involved in disease progression. But are the 
deletions the only mechanism of 9p21 inactivation? It is well know that in addition to deletions, 
the CDKN2A/B locus can also be inactivated by epigenetic silencing through DNA methylation 
or by point mutations. Methylation of CDKN2A and CDKN2B seems to lack prognostic 
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significance in ALL84, and the rate of point mutations has been extremely low in ALL1,78,85-89. In 
line with these findings, by a gene candidate deep sequencing screening of ARF, CDKN2A and 
CDKN2B, in our BCR-ABL1 positive ALL cohort point mutations were found at very low level 
with only a missense substitution in the exon 2 of CDKN2A (D146N). Additional mutations have 
been identified in the 5’ UTR/promoter of CDKN2A exon 1α at position 21965017, 191 bp 
before the start codon, with a heterozygous substitution of G > A and at position 21964851, 25 
bp before the start codon, with a heterozygous substitution of C >T. There are only few studies, 
mainly conducted on melanoma, addressing the possible impact of 5’-UTR/promoter variants on 
the transcription or translation of the protein. In one of them, the variant at -25 C >T, not 
observed in the control population, exhibited an intermediate impact on functional defects, 
proposing that this variant should be considered as potential mutation 131. Another study, on the 
other hand, indicates that the A-191G variant is probably a polymorphism and that is very 
unlikely to confer a high risk of melanoma, because it is present in the control population at 
approximately the same percentage as in melanoma cases 132,133. 
Moreover, frequent nucleotide variations, known as SNP, were identified in exons 2 and 3 of 
CDKN2A: rs3731249 G/A, rs11515 C/G and rs3088440 C/T. 9p21 is an important susceptibility 
locus for several diseases. The SNPS identified and here showed have been already reported to 
be phenotypically associated with solid tumors like non-Hodgkin lymphoma 134, breast cancer 
135
, colorectal cancer 136,137, and they are also associated with disease such Alzheimer 138 and 
melanoma 139, but their role in leukemia has not yet been well established and a larger number of 
patients is required to demonstrate any potential association.  
After having demonstrated that deletions are the main mechanism of inactivation, we 
investigated their implications in leukemia. Preliminary results have showed that in mice the 
combination of BCR-ABL1 and ARF loss are sufficient to induce aggressive B-cell ALL, 
increased self-renewal capacity, inhibition of apoptosis and independence on cytokines, 
contributing to resistance to targeted therapy with TKIs140,141. Moreover, recently Notta F. and 
colleagues142 showed that Ph+ ALL patient samples with a loss of CDKN2A/B had a tendency to 
poorer survival correlated with aggressive dissemination in xenografts and higher leukemia-
initiating cell frequency compared to patients with normal CDKN2A/B, demonstrating that loss 
of CDKN2A/B contributes to clonal predominance at diagnosis and competitive xenograft 
growth.  
How this may be translated in vivo in Ph+ ALL patients? In order to address this issue, we 
investigated the prognostic relevance of CDKN2A/B deletions in our study cohort. This matter is 
still controversial in literature with some studies suggesting that CDKN2A/B deletion is a poor 
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prognostic factor69,70,72,101,104,105, whereas others showing no correlation74,76,100. Beyond, 
Usvasalo et al. did not observe any difference in the incidence of deletion between diagnosis and 
relapse64. 
Our results showed that deletions of CDKN2A/B are significantly associated by univariate 
analysis with poor outcome in terms of overall survival (p = 0.0206), disease free survival (p = 
0.0010) and cumulative incidence of relapse (p = 0.0014). The negative prognostic impact of 
CDKN2A/B deletion on DFS was thereafter confirmed by also a multivariate analysis (p = 0051). 
These results show that there are genetically distinct Ph+ ALL patients with a different risk of 
leukemia relapse and that testing for CDKN2A/B alterations at diagnosis may aid risk 
stratification. Furthermore, the awareness that genetically distinct patients experience different 
responses to treatment points to the need to develop more effective therapies able to eradicate all 
genetic leukemia cells and to prevent disease recurrence. Since the loss of CDKN2A/B eliminates 
the critical tumor surveillance mechanism and allows proliferation, cell growth and tumor 
formation by the action of Mdm2 and CDK4/6, attractive drugs could be represented by the 
inhibitors of Mdm2 143 and CDK4/CDK6 144. 
In conclusions, our findings indicate that the inactivation of CDKN2A/B locus is a frequent event 
in Ph+ ALL. Deletions are frequently acquired at the leukemia progression and work as a poor 
prognostic marker, impairing overall survival, disease free-survival and cumulative incidence of 
relapse. Novel treatment strategies targeting the ARF-Mdm2-p53 and the CDKN2A/B-CDK4/6-
Retinoblastoma pathways may be effective in this subset of patients and in vitro studies are 
ongoing to confirm this hypothesis. 
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 CDKN2A/ARF/CDKN2B
1. NCBI Reference Sequences (RefSeq)
Cyclin-dependent kinase inhibitor 2A isoform 4
http://www.ncbi.nlm.nih.gov/gene/1029
NM_058195.3: mRNA-cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4), transcript variant 4
Total range: NC_000009.11 (21,967,751
Total length: 26,740 
mRNA product length: 1,164 
Related Ensembl: ENSP00000355153
Transcript Variant: This variant (4), also known as 
may use an alternative upstream start codon, which would produce an isoform that is 41 aa longer at the N
or an alternative downstream start codon, which would produce an isoform (smARF, described in PMID:16713577)
that is 47 aa shorter at the N-terminus; it is unclear if the isoforms derived from the alternative start codons are 
present in vivo. The p14ARF isoform is known to be nucleoplasmic but may also be recruited to mitochondria, as 
described in PMID:20107316. 
ENSEMBL card  
Cyclin-dependent kinase inhibitor 2A isoform 4
http://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=co
21995300;t=ENST00000361570 
HGNC Symbol: CDKN2A-201  
Transcript ENST00000361570 
Gene ENSG00000147889 
Protein product ENSP00000355153 
Location Chromosome 9: 21,967,997
Total length: 26,493 
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Gene type Known protein coding 
Transcript type Known nonsense mediated decay 
Strand Reverse 
Base pairs 905 
Amino acids 173 
ENSEMBL card 
http://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000147889;r=9:21967752-
21995300;t=ENST00000530628  
HGNC Symbol: CDKN2A-004  
Transcript ENST00000530628 
Gene ENSG00000147889 
Protein product ENSP00000432664  
Location Chromosome 9: 21,967,997-21,994,490  
Total length: 26,493 
Gene type Known protein coding 
Transcript type Known protein coding 
Strand: Reverse  
Base pairs:905 
Amino acids :132  
 
2. NCBI Reference Sequences (RefSeq) 
Cyclin-dependent kinase inhibitor 2A isoform 1 
http://www.ncbi.nlm.nih.gov/nuccore/NM_000077.4 
NM_000077.4: mRNA-cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4), transcript variant 1 
total range: NC_000009.11 (21,967,751-21,975,132) 
total length: 7,382 
mRNA product length: 1,267  
Related Ensembl: ENSP00000307101, ENST00000304494 
Transcript Variant: This variant (1), also known as alpha, contains an alternate open reading frame (ARF), when 
compared to variant 4. The ARF results from an alternative splicing between a downstream first exon, which 
contains the translation start codon, and the common second exon. Thus, the protein encoded by this variant 
(isoform 1) lacks sequence similarity to the protein product of variant 4. Isoform 1 is also called p16INK4a. 
ENSEMBL card 
HGNC Symbol: CDKN2A-001 
Transcript ENST00000304494 
Gene ENSG00000147889 
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Protein product ENSP00000307101 
Location Chromosome 9: 21,967,752-21,975,097 
Total length: 7,345 
Gene type Known protein coding 
Transcript type Known protein coding 
Strand Reverse 
Base pairs 1,218 
Amino acids 156 
 
3. NCBI Reference Sequences (RefSeq) 
Cyclin-dependent kinase inhibitor 2A p12,variant 3  
http://www.ncbi.nlm.nih.gov/nuccore/NM_058197.4 
NM_058197.4: mRNA-cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4), transcript variant 3 
total range: NC_000009.11 (21,967,751-21,974,826) 
total length: 7,076  
mRNA product length: 1,235 
Related Ensembl: ENSP00000369496, ENST00000380151 
Transcript Variant: This variant (3) contains an alternate open reading frame (ARF), when compared to variant 4. 
The ARF results from an alternative splicing between a downstream first exon, which contains the translation start 
codon, and the common second exon. Thus, the protein encoded by this variant (p12 or isoform 3) lacks sequence 
similarity to the protein product of variant 4. This variant is specifically expressed in pancreas, and has been 
described in PMID:10445844. It is a candidate for nonsense-mediated mRNA decay (NMD), but it is not known if 
the endogenous protein is expressed in vivo. 
ENSEMBL card 
Cyclin-dependent kinase inhibitor 2A p12,variant 3  
http://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000147889;r=9:21967752-
21995300;t=ENST00000380151 
HGNC Symbol: CDKN2A-003 
Transcript ENST00000380151 
Gene ENSG00000147889 
Protein product ENSP00000369496 
Location Chromosome 9: 21,968,179-21,974,826 
Total length: 6,647  
Gene type Known protein coding 
Transcript type Known nonsense mediated decay 
Strand Reverse 
Base pairs 794 
Amino acids 116  
 Synonyms CDK4I, INK4B, MTS2, P15, p15INK4b, TP15
1. NCBI Reference Sequences (RefSeq)
Cyclin-dependent kinase 4 inhibitor B isoform 1
http://www.ncbi.nlm.nih.gov/nuccore/NM_004936.3
 NM_004936.3: mRNA-cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4), transcript variant 1
total range: NC_000009.11 (22,002,902
total length: 6,411  
mRNA product length: 3,878  
Amino acids 138 
Related Ensembl ENSP00000276925
Transcript Variant: This variant (1) encodes the longer isoform (1).
ENSEMBL card 
Cyclin-dependent kinase 4 inhibitor B isoform 1
HGNC Symbol: CDKN2B-001  
Transcript ENST00000276925 
Gene ENSG00000147883 
Protein product ENSP00000276925 
Location Chromosome 9: 22,002,902
Total length 6378  
Gene type Known protein coding 
Transcript type Known protein coding
Strand Reverse 
Base pairs 3,829 
Amino acids 138 
2. NCBI Reference Sequences (RefSeq)
Cyclin-dependent kinase 4 inhibitor B isoform 2
http://www.ncbi.nlm.nih.gov/nuccore/NM_078487.2
M_078487.2: mRNA-cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4), transcript variant 2
CDKN2B 
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total range: NC_000009.11 (22,002,902-22,009,312)  
total length: 6,411  
mRNA product length: 4,001  
Amino acids 78 
Related Ensembl ENSP00000369487, ENST00000380142 
Transcript Variant: This variant (2) uses a different splice site, which leads to a translation frame shift, when 
compared to variant 1. The resulting protein (isoform 2) is shorter and has a distinct C-terminus when compared to 
isoform 1. 
ENSEMBL card 
HGNC Symbol: CDKN2B-002  
Transcript ENST00000380142 
Gene ENSG00000147883 
Protein product ENSP00000369487 
Location Chromosome 9: 22,005,986-22,009,271 
Total length: 3,285  
Gene type Known protein coding 
Transcript type Known protein coding 
Strand Reverse 
Base pairs 859 
Amino acids 78 
  
 NCBI Reference Sequences (RefSeq)
CDKN2B antisense RNA 1 (non-protein coding
http://www.ncbi.nlm.nih.gov/gene/100048912
NR_003529.3: CDKN2B antisense RNA (non
total range: NC_000009.11 (21,994,790
total length: 126,307 
processed length: 3,837 
product length: 3,85 
Source sequence(s) AL354709,BC038540,CB109081,DQ485453
ENSEMBL card 
HGNC Symbol: CDKN2B-AS-004 
Transcript ENST00000428597 
Gene ENSG00000240498 
Location Chromosome 9: 21,994,790
Gene type Known processed transcript
Transcript type Known antisense 
Strand Forward 
Base pairs 3,835 
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